0000950170-24-116847.txt : 20241024 0000950170-24-116847.hdr.sgml : 20241024 20241024070508 ACCESSION NUMBER: 0000950170-24-116847 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20241022 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20241024 DATE AS OF CHANGE: 20241024 FILER: COMPANY DATA: COMPANY CONFORMED NAME: EyePoint Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001314102 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 262774444 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-51122 FILM NUMBER: 241390701 BUSINESS ADDRESS: STREET 1: 480 PLEASANT STREET STREET 2: SUITE B300 CITY: WATERTOWN STATE: MA ZIP: 02472 BUSINESS PHONE: 617-926-5000 MAIL ADDRESS: STREET 1: 480 PLEASANT STREET STREET 2: SUITE B300 CITY: WATERTOWN STATE: MA ZIP: 02472 FORMER COMPANY: FORMER CONFORMED NAME: pSivida Corp. DATE OF NAME CHANGE: 20080619 FORMER COMPANY: FORMER CONFORMED NAME: pSivida LTD DATE OF NAME CHANGE: 20050111 8-K 1 eypt-20241022.htm 8-K 8-K
0001314102false00013141022024-10-222024-10-22

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 22, 2024

 

 

EyePoint Pharmaceuticals, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

000-51122

26-2774444

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

480 Pleasant Street

 

Watertown, Massachusetts

 

02472

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (617) 926-5000

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, par value $0.001

 

EYPT

 

The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 


Item 8.01 Other Events.

On October 24, 2024, EyePoint Pharmaceuticals, Inc. issued a press release announcing the first patient dosed in the Phase 3 LUGANO clinical trial of DURAVYUTM, formerly EYP-1901, for the treatment of wet age-related macular degeneration ("wet AMD"). A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

 

Exhibit No.

Description

99.1

 

Press Release of EyePoint Pharmaceuticals, Inc. dated October 24, 2024

104

 

Cover Page Interactive Data File (embedded within the inline XBRL document)

 


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

EYEPOINT PHARMACEUTICALS, INC.

 

 

 

 

Date:

October 24, 2024

By:

/s/ George O. Elston

 

 

 

George O. Elston
Chief Financial Officer

 


EX-99.1 2 eypt-ex99_1.htm EX-99.1 EX-99.1

img96707757_0.jpg

 

Exhibit 99.1

EyePoint Pharmaceuticals Announces First Patient Dosed in Global Phase 3 LUGANO Clinical Trial of DURAVYUTM for the Treatment of Wet Age-Related Macular Degeneration

 

– Second Phase 3 LUCIA pivotal trial first patient dosing expected by end of 2024 –

 

– Topline data anticipated in 2026 –

 

WATERTOWN, Mass., October 24, 2024 (GLOBE NEWSWIRE) – EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that the first patient has been dosed in the Phase 3 LUGANO clinical trial of DURAVYUTM, formerly EYP-1901, for the treatment of wet age-related macular degeneration (wet AMD). DURAVYU is an investigational sustained delivery therapy delivering patent-protected vorolanib, a selective tyrosine kinase inhibitor formulated in proprietary bioerodible Durasert E™.

 

“Dosing the first patient in the global Phase 3 LUGANO trial represents a significant milestone for EyePoint and DURAVYU, underscoring our leadership in sustained-release ocular drug delivery and commitment to developing innovative therapies for patients with serious retinal diseases,” said Jay S. Duker, M.D., President and Chief Executive Officer of EyePoint. “Our Phase 3 LUGANO and LUCIA trials were designed for potential global regulatory and commercial success based on our alignment with the FDA, as they follow a proven non-inferiority approval pathway. We have entered Phase 3 leveraging learnings from our robust DAVIO and DAVIO 2 clinical trials to facilitate accelerated enrollment so that wet AMD patients may receive this potentially paradigm-shifting treatment as fast as possible.”

“With over 150 clinical trial sites already committed, we believe we are well positioned to rapidly enroll patients globally in the pivotal LUGANO trial, with the LUCIA trial to quickly follow,” said Ramiro Ribeiro, M.D., Ph.D., Chief Medical Officer of EyePoint. “We are encouraged by the exceptional patient and investigator enthusiasm for our Phase 3 protocol, which aligns with clinical practice by including active treatment through trial duration. Patients will receive DURAVYU every six months or on-label aflibercept every two months, beginning after three loading doses of aflibercept with randomization occurring on Day 1. Further, the trials include both treatment-naïve and treatment experienced patients, which we believe more accurately represent the real-world patient population and increases our probability of success based on the positive DAVIO 2 data. We are optimistic that DURAVYU has the potential to change the current treatment paradigm and revolutionize clinical outcomes for patients suffering from serious retinal diseases.”

“Wet AMD patients face significant unmet need for a safe and efficacious sustained delivery treatment, as the current standard of care requires frequent injections resulting in a high treatment burden and, ultimately, delayed or missed appointments that potentially leave patients with no active drug to prevent disease progression and associated vision loss,” said Dr. Carl Regillo, M.D., FACS, Director of Retina Service at Wills Eye Hospital and Professor of Ophthalmology at Thomas Jefferson University. “Based on the promising clinical data generated in the DAVIO and DAVIO 2 trials, as well as the favorable safety profile from over 190 patients treated, I believe DURAVYU has the potential to improve the treatment paradigm for this lifelong disease by maintaining a majority of patients with active disease with no supplemental anti-VEGF therapy for six months or longer. The pivotal trials of DURAVYU in wet AMD represent an exciting milestone for patients, caregivers and physicians as we work to improve quality of life and patient vision.”


img96707757_0.jpg

 

“Despite new treatments entering the wet AMD market, there remains a need for safe and durable treatments that provide sustained treatment while decreasing the patient’s need for frequent injections,” said Ashkan M. Abbey, M.D., a principal investigator in the LUGANO clinical trial and Director of Clinical Research at Texas Retina Associates. “DURAVYU brings a new mechanism of action with the potential to treat wet AMD patients every six months or longer to actively safeguard patients’ vision between visits. We are proud to be the first site to treat a patient in the LUGANO clinical trial, and we look forward to continuing to collaborate with EyePoint to rapidly enroll patients.”

LUGANO and LUCIA are global, randomized, double-masked, aflibercept controlled, non-inferiority Phase 3 trials assessing the efficacy and safety of DURAVYU in patients with active wet AMD including previously treated and treatment-naïve patients. Each trial is expected to enroll approximately 400 patients globally who will be randomly assigned to a 2.7mg dose of DURAVYU or an on-label aflibercept control. The LUGANO and LUCIA trials are the only sustained release wet AMD pivotal Phase 3 trials evaluating re-dosing in both trials. Patients in the DURAVYU treatment arm will receive an intravitreal injection of DURAVYU every six months, starting at month two of the trial. DURAVYU is delivered via a standard intravitreal injection in the physician's office, similar to current standard practice with FDA approved anti-VEGF treatments. The primary endpoint of the Phase 3 pivotal trials is the average change in best corrected visual acuity (BCVA) at weeks 52 and 56 versus baseline. Secondary endpoints include safety, reduction in treatment burden, percentage of eyes free of supplemental aflibercept injections and anatomical results as measured by optical coherence tomography (OCT).

About Wet AMD

 

Age-related macular degeneration (AMD) is a leading cause of vision loss and irreversible blindness in people over the age of 50. Wet AMD is an advanced form of condition that develops when abnormal blood vessels grow into the macular retina, leaking blood or fluid, and leading to potentially severe vision loss. Wet AMD is a lifelong disease that requires continuous treatment so that patients may maintain visual function. Although multiple treatments are now available, challenges still exist as the current standard-of-care is dosed on average every two months in the United States under a treat-and-extend protocol, and these large molecule anti-VEGF treatments only target one pathology of the disease. This lifetime of frequent treatment represents a tremendous burden for patients, physicians, and the health care system, potentially leading to patient noncompliance and further vision loss.

 

About DURAVYUTM

 

DURAVYUTM, f/k/a EYP-1901, is being developed as a potential paradigm-altering treatment for patients suffering from VEGF-mediated retinal diseases. DURAVYU delivers vorolanib, a potent, selective and patent-protected tyrosine kinase inhibitor (TKI) as a solid bioerodible insert using EyePoint’s proprietary sustained-release Durasert E technology. Vorolanib brings a new mechanistic approach to the treatment of VEGF-mediated retinal diseases as a pan-VEGF receptor inhibitor, inhibiting all VEGF receptors. Further, in an in-vivo model of retinal detachment, vorolanib demonstrated neuroprotection and may have antifibrotic benefits as it also blocks PDGF. DURAVYU is shipped and stored at ambient temperature and is administered with a standard intravitreal injection in the physician's office. DURAVYU is immediately bioavailable with zero-order release kinetics release for up to nine months.

 

Positive data from both the Phase 1 DAVIO and Phase 2 DAVIO 2 clinical trials of DURAVYU in wet AMD demonstrated clinically meaningful efficacy data with stable visual acuity and CST and a favorable safety profile. Further, data from DAVIO 2 demonstrated an impressive treatment burden reduction of approximately 88% at eight months, six months after treatment with DURAVYU, with over 80% of patients


img96707757_0.jpg

 

supplement-free or receiving only one supplemental anti-VEGF injection through up to eight months, six months after treatment with DURAVYU. The data from the DAVIO 2 clinical trial supported the advancement of the wet AMD program and the initiation of the Phase 3 LUGANO trial, with the LUCIA pivotal trial to follow by year end 2024.

 

DURAVYU is also currently being studied in the Phase 2 VERONA trial for diabetic macular edema (DME). Topline data is expected in the first quarter of 2025.

 

About EyePoint Pharmaceuticals

 

EyePoint (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative therapeutics to help improve the lives of patients with serious retinal diseases. The Company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. The Company’s lead product candidate, DURAVYU (f/k/a EYP-1901), is an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with bioerodible Durasert E. DURAVYU is presently in Phase 3 global, pivotal clinical trials as a sustained delivery treatment for wet age-related macular degeneration (wet AMD), the leading cause of vision loss among people 50 years of age and older in the United States, and in a Phase 2 clinical trial in diabetic macular edema (DME). EyePoint expects topline data from the Phase 2 clinical trial in DME in Q1 2025 and topline data from both Phase 3 pivotal trials in wet AMD in 2026.

 

Pipeline programs include EYP-2301, a TIE-2 agonist, razuprotafib, formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The proven Durasert® drug delivery technology has been safely administered to thousands of patient eyes across four U.S. FDA approved products. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts.

 

Vorolanib is licensed to EyePoint exclusively by Equinox Sciences, a Betta Pharmaceuticals affiliate, for the localized treatment of all ophthalmic diseases outside of China, Macao, Hong Kong and Taiwan.

 

DURAVYU™ has been conditionally accepted by the FDA as the proprietary name for EYP-1901. DURAVYU is an investigational product; it has not been approved by the FDA. FDA approval and the timeline for potential approval is uncertain.

 

Forward Looking Statements

EYEPOINT PHARMACEUTICALS SAFE HARBOR STATEMENTS UNDER THE PRIVATE SECURITIES LITIGATION ACT OF 1995: To the extent any statements made in this press release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements regarding our expectations regarding the timing and clinical development of DURAVYU in wet AMD and DME, including our expectations regarding the enrollment, dosing and data readouts for the LUGANO trial and the LUCIA trial; our optimism that that DURAVYU has the potential to change the current treatment paradigm and revolutionize real-world outcomes for patients suffering from serious retinal diseases; our belief that DURAVYU has the potential to maintain a majority of patients with active disease with no supplemental anti-VEGF therapy for six months or longer; our expectations regarding the timing and clinical development of our other product candidates, including EYP-2301; and other statements identified by words such as “will,” “potential,” “could,” “can,” “believe,” “intends,” “continue,” “plans,” “expects,” “anticipates,” “estimates,” “may,” other words of similar meaning or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties


img96707757_0.jpg

 

and risks may cause EyePoint’s actual results to be materially different than those expressed in or implied by EyePoint’s forward-looking statements. For EyePoint, these risks and uncertainties include the timing, progress and results of the company’s clinical development activities; uncertainties and delays relating to the design, enrollment, completion, and results of clinical trials; unanticipated costs and expenses; the company’s cash and cash equivalents may not be sufficient to support its operating plan for as long as anticipated; the risk that results of clinical trials may not be predictive of future results, and interim data are subject to further analysis; unexpected safety or efficacy data observed during clinical trials; uncertainties related to the regulatory authorization or approval process, and available development and regulatory pathways for approval of the company’s product candidates; changes in the regulatory environment; changes in expected or existing competition; the success of current and future license agreements; our dependence on contract research organizations, and other outside vendors and service providers; product liability; the impact of general business and economic conditions; protection of our intellectual property and avoiding intellectual property infringement; retention of key personnel; delays, interruptions or failures in the manufacture and supply of our product candidates; the availability of and the need for additional financing; the company’s ability to obtain additional funding to support its clinical development programs; uncertainties regarding the timing and results of the August 2022 subpoena from the U.S. Attorney’s Office for the District of Massachusetts; uncertainties regarding the FDA warning letter pertaining to the company’s Watertown, MA manufacturing facility; and other factors described in our filings with the Securities and Exchange Commission. We cannot guarantee that the results and other expectations expressed, anticipated or implied in any forward-looking statement will be realized. A variety of factors, including these risks, could cause our actual results and other expectations to differ materially from the anticipated results or other expectations expressed, anticipated or implied in our forward-looking statements. Should known or unknown risks materialize, or should underlying assumptions prove inaccurate, actual results could differ materially from past results and those anticipated, estimated or projected in the forward-looking statements. You should bear this in mind as you consider any forward-looking statements. Our forward-looking statements speak only as of the dates on which they are made. EyePoint undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.

 

Investors:

Christina Tartaglia
Precision AQ
Direct: 212-698-8700

christina.tartaglia@precisionaq.com 

 

Media Contact:

Amy Phillips

Green Room Communications

Direct: 412-327-9499

aphillips@greenroompr.com

 


GRAPHIC 3 img96707757_0.jpg GRAPHIC begin 644 img96707757_0.jpg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

N?'/4O>\$R79#8>3AZ;57=R7<\"W M^KN<'&1+Q:A)#Z(D25/E1H,&-(FSILAF)#AQ&7),J7*DN)9CQHT=E*WGY#[R MR0A""-2E&1$1F8^-J*HLS.R)VV6.WQQ6@O9W3Q&>26[VJK-=SS M#0R]-QADHSCF):I:F-D:51\&@SG#G>FI;3MU*F*0XZPF.HM<-L]HGGV:-4&_ MLZCC&GO2[Z>'OFM'O4M3Q(%FU_Z;<=P_D(:(\.^^KR8&Y\0\Q0 $;U=\TMFBPNC/\12_MI^- SFS_P!??FWRHKQ!?Q-@ +&_W9W[+G%/ MIGW!^-Z\:]](_P")I>9I\C(/GWK!^!$D""!F% M");[VA^KQQ)^F?-OF.R+4Z+/6%WYF/C$DV;^?J^ N4@O"["7 6A/:MY'\>( M7;OX;XW,WUIB)D6+\==55.2T,G:.#L76.VK&+0VGJR]JW;U$ZIL&7&5I4S(; M;<2I)D9=2,:T[3Y=F$MH+RHJ%9TY7$VGS)8-<[6GA@UQ%?YC0KN^JR4)\US> M&AZ=)L>J-TZX MCZDV\%K/"LTY8\6-;)=7L3DMQ_P%#"O*^K--R:ZQ9+*NC!^5U5YD<$FU=)+? M@?3_ ,1/_K%U]U'*LTN/J]M7J>#3G+D3.V-M<3]I3F^*+?L&OK"/;?:1%5Y!\E-[I&JH*GG)"*;&J2(W%HL4Q^.\\M35?6QHL)I2U& MAHC49G9]AEUCE=NK6PI1I4%N):WOMZY/A;;X214*%&WAY.A%1AP>SOOA9X>/ M<=IR%34VM_:UE%15EA=7=U80JFFIJF%)LK6VM;*2W#KZRLKX;;TN?83Y;R&F M66D+<=<624D:C(AQG.-.+G-J,(K%MZ$DM;;W$@VDL7H2+!SL-]G%[A1B:.3W M(RBC_P#%/L.@;D28RMA99#)L[5]ORKKHJCKFU% MYYIOT+MQMCT'_P >+TOO MGVEN;^O>)(XKLP0 5F'O!FR7-C=UODBTW*5)JM>Q]9ZVIB4:#.,WCNL\5E MW\7^:>>026\SM[0R+J2NBOC)2OS)+8_8*V5OLO;O#"=3GS?5G+#_ "J)/7UBD9GE-5C MC)L^8R3ZOJ61>7KX=1YKRX5I:5;IZJ=.4_@Q;]@X59^3I2J=[%OK+$N&ZVN@ MT]= J*N(S K*N%%KJZ#&03<>'!@L-QHD2.V7@VS'CM)0A)>!)(B&I,I2G)SD M\9-XM\+*Q;;>+UL^T?#X 1\_>9M7Q\[[8619BN,ER3I30>S4$IM1DA2TMJ/JI".D]Z.+ET-I8T<=%: MC.'62J?]!FL@JS[!7,#8,G $_SW5;8[N1\%-O:[ENJ=D:UY(7\ MB D_7\L?'LWP7![.)'+SH-CK^4%;:N'Y%]?YTO,A/@IRB.D^W5/.Z5PM52W6 M/'&4ER.)#-HJ?-O(S7NJ?93?L8$G<5L8 (EOO:'ZO'$GZ9\V^8[(M3HL] M87?F8^,239OY^KX"Y2"\+L)< !:$]BK[)WAO_0S-?TM[!&M.V_XIO/#C_+@5 M_F_K&KQKD1MJ$5,: 4Q@W +2 D">[._:C8I]#&X/Q17B!](_P"&9>>I M\K,-GWJ]^'$L;QKV08_D^PS)9>C266I$>0TXP^P^VAUE]EU!MNLO-.$I#C3B M%&E25$9*(^ACZFT\5K&HK?\ OP=K![@7OO\ O9U)C[K'%/>UQ.FX8U!CK57: MISUQMVQO]3RG4&M$6J6A+MACAN$UZE9ZL1!.KK7WG-A=A]IUGECZ+=R_]I02 MYV.N<=2GQ[D^'!Z.IIK!HXSA"K!TZBQA)8-%H1VINXWA/<@XS MT^QXBJVCW%A:8&+;VU_$=\JL;S(HRS9OJJ,ZXN2>&YLQ&7-K'%&LFS)Z(IQ; MT1Y0UIVHV>K;/9D[=XRM)XRI2WX[S]]'4^H]317^8V,[&X=-Z:3TQ>^M[C6[ MU]TV<"-F/ *EKN/?:'<\_P!\[E%^G#.1M1L]Z@L?[.C_ "XED6/U*CYJ M'BHPQ&8/4; >U+]I3P:_>;U)\[:X8':C\.WO]M4\5GBS+ZA6\V^0M$4WHZQWVM"5U#207Q^ M'9_1 '%W5-69#5S:6XB-3JVQ85'E1GDDI*T*\24D_A;=:61+0M/1 M2%I)23(R(QFMG=HLYV3SNVVBV?N*EKG%I552E4@\&FM:>Y*,EC&<'C&<'*,D MXMH:]!K&V[J:SUA<)3YG)^-V3CITML:2\WQ/CJK[ D$2&K".@_A(B0\@O.@B MZ+0C]HN@/IWR7IIV?-.I4\\ MHN/$>0B_CB &/\ OUPBK<=: MZ'U7.G.$?X")J.RDR/\ #U,W2Z?^@239Q?*U9>]7*^T:8_K*K1CD.26^#YTK MNO+'I:7Y!OK8-]A'@S18Y?5P M[QEJ2-8BO (_?O,7V7.5_3/I_\ &]@)YTXYLKGR-*,''FIZ4\=..])&V/[J9V\ M?SR\SOK#T?\ Y=A%OS0S_P"AL_@5/]TQWWBO>\I=:7QA]U,[>/YY>9WUAZ/_ M ,NP?FAG_P!#9_ J?[H^\5[WE+K2^,/NIG;Q_/+S.^L/1_\ EV#\T,_^AL_@ M5/\ ='WBO>\I=:7QA]U,[>/YY>9WUAZ/_P NP?FAG_T-G\"I_NC[Q7O>4NM+ MXP^ZF=O'\\O,[ZP]'_Y=@_-#/_H;/X%3_='WBO>\I=:7QA]U,[>/YY>9WUAZ M/_R[!^:&?_0V?P*G^Z/O%>]Y2ZTOC#[J9V\?SR\SOK#T?_EV#\T,_P#H;/X% M3_='WBO>\I=:7QA]U,[>/YY>9WUAZ/\ \NP?FAG_ -#9_ J?[H^\5[WE+K2^ M,/NIG;Q_/+S.^L/1_P#EV#\T,_\ H;/X%3_='WBO>\I=:7QCL&*>ZS=N+';,Q#*]DZUCXWD3#"_,NJNG\-TQB.5-U\HO!PX%G!D]/Y+ MJ1UU>DW:&I3E",+6$FL.=&$\5PKG5)1QXTUP'&6T-]*+25--[J3Q77DUV"1] M6UM?3UT"HJ846MJJJ%%K:VN@L-QH4"O@L-Q8<*)&92AJ/%BQFDH;0DB2A"2( MBZ$*]E*4Y.Z8-MMXO6S[1Q/@ ' 95BV.9SC&187F%)6Y+ MB>6T=KC638[<16IU3>T%Y!?K;>HLX;R5-2H%C DN-.MJ(R6A9D8[*56I0JQK M49.-6$DTUH::>*:X4SE&4H24XO"2>*?"5=O=L[=^1=N;E;D.MX[-A/TOG?MV M;Z$RR6E]XK/!Y,PTOXM8SW"4W)RK7\QY-?8?']5YKV::I#:)K:"V6V5V@I[0 MY7&X>"O(81JQWI8>V2[V6M=5;A8&6WT;ZV53_56B2X=_B>M=;<-7HDQD#)GA MYRJV5PKY&:SY(:JDI_*77MXB5,I),AZ/49EB\YM4#*L)O_1):E4^3TC[T9Q9 M)4Y&<4B0SY7V6EIQN;Y7;9SE]3+KI?)U(Z'NQDM,9+AB]/#J>ALZ+JWIW="5 M"I[62ZSW&N(M9^-/(;6W*[16M.0>I+9-M@NSL:B7]6I1H]NJI9FN)=XUV8WNK:#G.W<5#[1K#2>0?)^D*:SAI5#S3 MEN0]F?DDH4F32ZJ2ZVY%6E/1S('65MNDNM?:75_2+M)Z%;?8EI+_ )-:.-1K MW--^YXY[OO,='=)D=SZ_\E3]#I/Y2:[K@CO=7DXR>0*/(> $;U=\TMFBPNC/\ $4O[:?C0,YL_]??FWRHKQ!?Q-@ )E_9)[Q' SA9P M5H-'\@]G9)BNQH&RMBY))J:S6F?93%14Y#8Q)%6^5MCU!85JUOM-*-2"<-:. MG11$*@VSV2SS.,[E>V%.,K=TX+%SC'2EIT-ID7S;*[R[O'6HQ3AS4M:6KC-N M?WCKM/?GRS3ZD=M?V3$4_+W:GZ"'\2'QC&?869=XOA+MC[QUVGOSY9I]2.VO M[)A^7NU/T$/XD/C#["S+O%\)=L?>.NT]^?+-/J1VU_9,/R]VI^@A_$A\8?86 M9=XOA+MC[QUVGOSY9I]2.VO[)A^7NU/T$/XD/C#["S+O%\)=L?>.NT]^?+-/ MJ1VU_9,/R]VI^@A_$A\8?869=XOA+MC[QUVGOSY9I]2.VO[)A^7NU/T$/XD/ MC#["S+O%\)=L?>.NT]^?+-/J1VU_9,/R]VI^@A_$A\8?869=XOA+MC[QUVGO MSY9I]2.VO[)A^7NU/T$/XD/C#["S+O%\)=L?>.NT]^?+-/J1VU_9,/R]VI^@ MA_$A\8?869=XOA+MG\"=JO8V8X_A%9R+F4-IDUE%J*NPS/6.S,4QI-C- M>1'B,VN36V*LTM#'>><(CE3GH\1KX774)\1TW&P>T]O1E6E;J48K%J,X2>"W MDI8OB6+WD<9Y+F-.#FX8I;S3?6Q-SXAYB@ (EOO:'ZO'$GZ9\V^8[(M M3HL]87?F8^,239OY^KX"Y2"\+L)< !R<.ZN:Z).KZ^VLX,"S03=E"AS MY4:)8-DE:";G1F74,RT$AQ1='$J+HHR_"8X.$)-2DDY+5HU<1\:3>+2Q1Q@Y MGT #.[AKVUN8_/"_AUO'[4-U98JN:B)<;9REJ1BVH\:04@X\N1:9O.B MKB3WJ]2%*=@53=C;*2A7IQ'#+H,'F^T649'3")WW:^[&?';M\IJ-G9:]%WIR@1&-3FS;JL2QC6 M/RF3:EP=48Q)-\ZAQ+*U,KN9:G;62@U^F<-EY<4J0VEVUS#/L;:EC0RSO$], MN&]QIQ[BWWMU\;]C5QF\<0HQ !4]=T3().3=Q_G M58RO7)V-RNWMCZ?:);DQSV;$MC9!BL/RO.(0I#!Q*9'I-=/*PWY6DF:4$9[2 M;-4U3V>L8K4[6D_A04O9ZNLL;+X\VQHK_MQ?76)@B,X>PV&]I?&F,L[F'!ZK MD>EZ<7DAK3)4^MZOD]?"[Z/F,;IZ2D+]4I-$CR=3\OGZ>8C3U(X_M54=+9R] MDMVWFOA+F^R>+,I>3&U7'R$D1V4OK)S$)E3QD[$BE5PDFI#9>1;Q$M1^=LBIWI6I]U8 MU5CI59/>T>3:Y617:6.FC+PEXI,K%0D7 ");[VA^KQQ)^F?-OF.R+4Z+/6 M%WYF/C$DV;^?J^ N4@O"["7 6A/8J^R=X;_ -#,U_2WL$:T[;_BF\\./\N! M7^;^L:O&N1&VH14QH !3&#< M( "0)[L[]J-BGT,;@_%%>('TC_AF7GJ? M*S#9]ZO?AQ+&\:]D& Q[Y4\9-6[)CICE<8U%:G+'@:W M8O?4EH?8TG?;W%2UK1KTGA.+Z^^GP,JMN9_$7:G!SD5L#CEMV$2EZFR M&(PZU1YWAMEYW\7SK&W'37ZM/D->1+\GG4Y#E(>B/^63'>0C9W)\UM>ZGQ?XF+(RAZ#/CMN\]]C M=NSDWBF\\,*5=8I(]/&-O:^1))B)L+6L^9&>NJ_@UX[ZSA?6[HRT2UQ>\ M^UO\!:4:2W1K?D3J; =W:BR2)ENN-E8[#R;%;V&?0I$*5YVGXDV.H_6K[BHG MLO0Y\-TDOPIL=UAU*7&UI+6:]L[C+[JI97<7"XIRPDN'@WTUI3U---:"O:M* MI0J2I55A4B\&>ICRG6 %2UW'OM#N>?[YW*+].&#7[S>I/G;7# [4?AV]_MJGBL\69?4*WFWR%KD- M72N@ K*/>$?M?>77^X/_ )8=+#9#8+\)VG_E_G5"?9+ZLI?O M>/(TQB8&4,FN%/ZY7$G]YO0WZ5,4&-SGU1=?VU7Q)'1=?5:GFY)F/%F:*S(91*,1XY3Y73S:&^A-SJVB]ZD['YSBSI;HD=$O)+JKV*;Y2\C%DPC^4GP2XDO.CPZDG]H.@OITV?Z:- MG_2+?F6NU=K"/I=ISM,'J\M1QTSMYOVLM,JIQ M QHW]*)4S&H1&75F-92E)(_'I)=B M-(-1>;X/]$5T\/X?'^"5[.0PA5J;[BNMCVS0O]9=^JF9Y#E::YU*A=56MWY6 M=&$6]/\ V98:%NZ7N8]"2FE ;$^TA52;CN9\'XD0VB=9Y$Z\M5^LLT(]F MHK9%W-(C2E9FZ<.O<)!=.BE]",R(^I1_:J:ALW>MZO1YKKK!%A6\!E MK -7RNP (_?O,7V7.5_3/I_\;V GG1Q^)H^9J!(KD!L(3@ "P[]UT^S6OOWF]H_-+60H'I,_$4?[:'C3(3M!]?7FURL MD<"O3!@ :R^[#V]<:[C/%#)M5DBMK=O8>J3 MG.ALPG%Z*:/8,"$ZVFBLYJ"]9G$\ZA=:RR+HXVSZC,WTG7H3"2DFRV?U-GLT MC=:7:3[FK%;L&]:7?1>E;^F.*39[\MO96-RJG^D]$EP=M:UUMTJX<.JU/M.IJ%+78NFE2EQ\=V)45C==,)+;IH MLX]>XDFFU2W%5WM[LO4SBWCF%A#G9E2PBXK7.#>KC@WBN!RUZ#!9UETKJ"KT M%C7CHPWUVUKXL> UA]SWGMEW<2Y7YGO"V3/J<"KDGA>E\,F+1YL1UA339CM, MU,:84MC\HLADRWK2T62W>DV6IE#BH[+!)DFS61TMG\KA90P==]U4EWTWKZBT M1CP+'6V9#+[.-C;*BM,]TS,X"\+=B\^>3VON.VOD2(35]+^ M6,^S!,0Y<'7NMJAZ.O+,RL$FIME1P8KR(\)EQQM,VSDQHI+2IXC+#Y[G%OD6 M6U,PN-+BL(QW9S?M8KCUO>BF]P\MY=0L[>5>>YJ6^]Q?MN%JGH_2^N^.NHM> MZ/U/0LXUKO6.,5V*8O4M>13B(,!LS>G6$A#;7M]U<37'9D^6M/JRYLAU]SJM MQ1GK#>WEQF%W4O;J7.N*LG*3X7N+>26A+<22*[K59UZLJU1XSD\6>J#RG6 M $;U=\TMFBPNC/\ $4O[:?C0,YL_]??FWRHKQ!?Q-@ M "X_UO\ ^7>!?T+Q;\1P1J+<_6*GARY65A4^M+F=G][2_(J:Y\A:TOLI)3*$N*-#!XS'MRD MRS)H^D=OSOJ,R(D&:DD?*GM5LY4]K>V^O#3-1\;#KZCZLRL):JU/KX6=(N4EQ49-OQRW#6JD):-).J83,PYDW4MFM)*-/7IU+K\(]< M,]R2I\W>6LL-ZK3?_4=BO+.7M:M-_O1[9TRRXF9C1N(G)^1(D.ML,,,:"VLZ\^\ZLFVF66F\34MQUQ:B2E* M2,U&?0AUO.=A\8^>EVJ_P!6G\)=L]>QCM5=R?+EDBJX,\H(BC=> M9ZY/IW,\(1YV&4/K,W,SJZ!LFE(61(7U\CB^J$F:R-)>2KM/L[2]M>VS\&I& M7BMG5+,;".NM3ZDD^3$R^US[NYW6\_>C?*&@:'6E;)=:;*WV-MG6<%EE"UNH M=?DT^,9-E>5L-1C;(U$JN\ZB6DVTK+KTQ-QM_LO03YM>522W(0F^RU&/9/+4 MSO+H:IN3X$_9279-F.E?=,]QVBXLOD/RNUQA3"5MN2J33V'9)L>7)8,NJXJ< MAS%W6<:KE%UZ&X5=/;29>"5%XB.7G2G9QQ67VM2;WZDE#L1Y^/71X*NTE):* M%.3\)I=A8\IO)XR>[V]M/CA*K[VSU9;\ALOK_2<;O>0EQ&S6H3((DJ?\NNJR MLQ[6LR*MY/5M%A4SW6DD22=,S4I4*S+;[:/,$X1JJWI/Z.SI?9-UE/35&/55?14%56T=)4Q&*^JIZ>#%K*JL@16R:C0J^ MOA-,1(42.TDDH;;0E"$ET(B(0V?9/-0VX1FE,JMUCG-C!?+H9?'C38K;B?_M((1;;5N.R]XUK\FNS M.*9CLW>&75<.]7*BT4&M!7P &OWNM_9J\Y/W9-M?-.P&> MV7_$=E_&_\ 0S-?TM[!&M.V_P"*;SPX_P N!7^;^L:O M&N1&VH14QH !3&#< M( "0)[L[]J-BGT,;@_%%>('TC_AF7GJ?*S#9]ZO M?AQ+&\:]D& #2;WNNU] [AO'15_KZK@L\H-(P+:^U-8^1F,_F]0MM,O(=1 MVL]7IDJ/D91B>J%OJ]*%<(1\=EB5,6J9;&;2RR#,/)W#?V;6:4UWKW*B7![K M#7'?:1ELIS!V5?FS^KST/@WI=3=X.H5I=E6V--8SZBW@3:JVJILJMM*NRBOP M;&ML8+[D6; GPI3;4F'-AR6E-NM.)2MM:32HB,C(;&1E&<5.#3@UBFM*:>II MD\336*TIGQ#D"2;[OCW74<0]L)XJ;UR3V;C;N_(XJ<9R"XF&BLTQMBS4U AW M+LE]9,5F"YTKT8=RI?2/!EHC3U*8938+=KK;W9;[6M?M2QCCF-&.E+74@M.' M#*.N.ZUC'2^;A@LZR[TFGZ317R\%I7?+MK^T.YY_O MG*SQ9E]0K>;?(6N0U=*Z "LH]X1^U]Y=?[@_\ MEATL-D-@OPG:?^7^=4)]DOJRE^]X\C3&)@90R:X4_KE<2?WF]#?I4Q08W.?5 M%U_;5?$D=%U]5J>;ER,MV1JB5H !!BM8#E5:656Z MHU.UL^9 <4;:FC4Y#D.1UJ-I1FILS4V?Q3/J7P#\/+JWE:W52UGIE3J2@]&& MF+:U;FK4?T/65S&]LZ5Y#1"K2C-:<=$HJ2T[NO7NGP#H/2 <'D> M.4^5T\VAOH3XG:YQ:SYT)QU->ZA..J=.:[F<)8QE%X,^-8Z&:R-KZHN-8W'HO>I.Q M^;]K+3*G)^3J:>;*?1*/-XCR<7J<0 M ##O=%@4W-WV$J\R:NO@P?#IY26I*YZR+IX&9' M-Z'^'J73\'03?(J7D[!2>N2V7O):---+X4XQ]DQV;RYN757[ MU+KM(M%!K05\ !'[]YB^RYROZ9]/_C>P$\Z./Q-' MS-3D1FLA]8+P)%<@-A"< 6'?NNGV:U]^\WM'YI:R% ])GXBC_;0\:9"=H/K MZ\VN5DC@5Z8, (7'O,_;,S'V5U2&F+?)0 ']&&'I+S, M:,R[(D2'6V&&&&UNO/O.K)MIEEILE+<=<6HDI2DC,S/H0^-I+%ZAJ+*WL6=L MY' +C"UE.QZ5,;DSOZ)397M4IC+9V& T+++LC$-2L.^)QW<>CSERKDD=/5NI M+K1K>9AQ5EKIMMM']NYEY*W>.6T&XPWI/W4^KAA'WJ3T-L@>;W_IMQS:;_X\ M-"X=^75W.#C-X0A9B0 "./[T7]FM0_O-ZN^:6S1871G^(I?VT_&@ M9S9_Z^_-OE17B"_B; ;J>#78DY<\_\ 0M?R(TWL7CCC6%663Y)BC%7LS+MF MTV4HL<7DLQ;!YV%BVHV^4Y#?/+[RG<2K* M*EC",''"6K3*I%]@Q5WG%M95O(58U'/!/0EAIXY(S"^ZF=P[\\O#'ZP]X?Y= MAB?S0R#Z&\^!3_W3R_>*R[RKUH_&'W4SN'?GEX8_6'O#_+L'YH9!]#>? I_[ MH^\5EWE7K1^,/NIG<._/+PQ^L/>'^78/S0R#Z&\^!3_W1]XK+O*O6C\8?=3. MX=^>7AC]8>\/\NP?FAD'T-Y\"G_NC[Q67>5>M'XP^ZF=P[\\O#'ZP]X?Y=@_ M-#(/H;SX%/\ W1]XK+O*O6C\8?=3.X=^>7AC]8>\/\NP?FAD'T-Y\"G_ +H^ M\5EWE7K1^,/NIG<._/+PQ^L/>'^78/S0R#Z&\^!3_P!T?>*R[RKUH_&'W4SN M'?GEX8_6'O#_ "[!^:&0?0WGP*?^Z/O%9=Y5ZT?C#[J9W#OSR\,?K#WA_EV# M\T,@^AO/@4_]T?>*R[RKUH_&.W8'[J%S1F9;1Q]G;_XOX]@CD]C\I;; [O:^ M99;%K"<2YC@EUU)\A/(IJN-1U%520C=.'3UL&KB&^LG M'CC5\5J(P;RTI0E;IM,EYC))$9_@(4?.3G-SEK;;ZY#V^%/ MT,5GXWN!K'M?^)KSSSY$5YFGK"KX9LV$;/ !43< MUOURN6W[S>^?TJ96-KLF]46O]M2\2)9=K]5I^;CR(QE&2.\VT]BO[6'AO_33 M-/T2[!$5VV_"UYX$?'B8W-_5M7B7*BT*&M)7X &OWNM_9 MJ\Y/W9-M?-.P&>V7_$=E_P1K3MO^*;SPX_R MX%?YOZQJ\:Y$;:A%3&@ %,8-P"T@ ) GNSOVHV*?0QN#\45X@?2/^&9>> MI\K,-GWJ]^'$L;QKV08 A)^\E]JM6,7-EW$-#8TK\GEON&JTSK6D1"69/7I(GTI M,2C)]V-8R!1/2!LO]G7+SBQCA85I=VEJIU'N\$9[FXI8K0G%$-SO+O(5/2J* M^1D]*[U]I\O4)/XK4CX %2UW'OM#N>?[YW*+].&HV ]J7[2G@U^\WJ3YVUPP.U'X=O?[:IXK/%F7U"MYM\A:Y# M5TKH *RCWA'[7WEU_N#_ .6'2PV0V"_"=I_Y?YU0GV2^K*7[ MWCR-,8F!E#)KA3^N5Q)_>;T-^E3%!C<\KL3R*+S*4HB/XQ]>H_&;I#L/LO;[.\OPPC1S6[BO!5>?->MO3'!Z6 MWOZ3][.B[,OMCHUV?S3'&5?);*B<)K&,X23C.+<9)IM'QI-8,U ME[K88Q8.K*GN#074CZ&OY.L?(1(9L&4$?0^A(?07G1TZ+0C]F^ M@3I[R+IHR+FR\G:[:6M->E6N.O4O2+?%XSH3>&*QR?B]MIM!/ M:O:W,MHYXX7M[5JQ3]S"4WY./[L.;%<".''>1@ ) 'NT&!KR_NCXAD*8OM M"=5Z;W#GCCOH$]["BQHX>L"E>H<=XXOG/!\_P#Z,3#9]/FY>X]]**]GV"QS&O9!@ M (_?O,7V7.5_3/I_P#&]@)YTEEAA[*, M/DH75VR"2VHY$U:7T+>MM:LK M;>+UK\_WA!]GG0K=MIXC*=1:I;<:G*41);/=M:XTWN<#GJ\''?3(_GM_Y"EZ)2?RLUIX(_X\F/ 3[Q11#0 M (X_O1?V:U#^\WJ[YI;-%A=&?XBE_;3\:!G-G_ *^_-OE17B"_B; 6-_N MSOV7.*?3/N#\;UXU[Z1_Q-+S-/D9!\^]8/P(D@00,PH M 1+?>T/U>.)/TSYM\QV1:G19ZPN_,Q\8DFS?S]7P%RD%X782X "T][, M_P!ESPI^ABL_&]P-8]K_ ,37GGGR(KS-/6%7PS9L(V> M "I Y]4_Y/<[.:E![1[7\A\M.1U/[7Z/L_M7R;N+,H7M'H>J]Z/K>CYO M)YU^7KT\Q].HVKR*?E,DLZFKG6M)]>G%EDV;YUG2EOTX^*C$L94])M-[)=NJ MD[J?"^8EA,@WMGSJ@VU.&V24Y!A.5T*W_,25]51461NDGI\8T>7J77J48VRA MS]F+Q?\ :3ZTHOV#'YLL+5J78VVW9$)DTFHG#4^S5R%$9$9%Z9]3(S+K4G2K)>1LH^ZP38A31% B6^]H?J\<2?IGS;YCLBU.BSUA=^9CXQ)-F_GZ MO@+E(+PNPEP %H3V*OLG>&_]#,U_2WL$:T[;_BF\\./\N!7^;^L:O&N1&VH1 M4QH !3&#< M( "0)[L[]J-BGT,;@_%%>('TC_ (9EYZGRLPV?>KWX<2QO M&O9!@ #K^6XGC6>8MDF$9G15F3XAF%%;8QE.-W<1F?3W^/7L!^LN::T@R M$K8F5]E7RG&7FUD:5MK,C^$=E*K4H58UJ,G&M"2E%K0TT\4T]],Y1E*$E.#P MDGBGO,K"^[[VULD[;_)JPQ.L9L[70&S%VF6:$S&=YY#KV.MRFCM,$O)WBA_+ M=?/SF8LE9^54V([%F^1OVDV6MD]D]HJ>T.6JK+!7]/"-6*W]R27>SPQ6\\8[ MF+G^67\;ZWYSP5:.B2X=_B?^!J@$I,B>@:IVGGVD-DX1MW5N2V&'[#UWD=9E M>(Y)6+),JLN*F0F1'6IMQ*X\R%())LR8KZ'(TN,XXR\A;3BT*\]U:T+VWG:7 M45.WJ1<9)[J?[:&M*>E:3A4IPJTW2J+&$E@T6CG;![A&!]QKC'CNWZ+Y-I-D MT)1,6W=KV)(4MW"M@1XI+DN1&7UKEJQ/*6D'/IWUJ<\T9:F%N*D1I!)UGVER M"OL]F4K2>,K>7=4Y]]'XT=4EOZ=317V864[&X=)Z:;TQ>^NVMTV+B/GA*EKN M/?:'<\_WSN47Z<,Y&U&SWJ"Q_LZ/\N)9%C]2H^:AXJ,,1F#U&P'M2_:4\&OW MF]2?.VN&!VH_#M[_ &U3Q6>+,OJ%;S;Y"UR&KI70 5E'O"/V MOO+K_<'_ ,L.EALAL%^$[3_R_P ZH3[)?5E+][QY&F,3 RADUPI_7*XD_O-Z M&_2IB@QN<^J+K^VJ^)(Z+KZK4\W+D9;LC5$K0 "* M+W+,15B?,/9KB&U-P\J8Q;+H/FZ=5IM,:K(UDYU)*2-*KZOE]/#P+P,S,C,_ MRK_4EE+RKI?S.26%&ZC0KQX>?1@IO^+"I_\ 4_9G])^=K.N@W*(R:=>SE<6T M^#R=>I*FOX,Z>/8P6@P-%$FQP <7$HM;C6E2C)8QG"2<)Q;C*+BVG\PQUFM'<.GK/6=G[1']:PQ2P>457:& MGS.1G%>995EF:$DAN8V@C\B^A(?01J21&2T(_93]/OZ@LEZ9(\6&QIP M ,D>-/"[!*^0H M;,6JQI$U3C+$.VS*_LHM7#=<6EMAV2;[G\RRZ:>JIF=GE-6C=7N/D/+13PX] M>&ZHI8M;J6"TLH7]26WE#8/HKO:SGS;_ #%JQHX/!XUU)59+#2N90C5DFM4E M%8IM&F6[I;C&KFWQW(:NPH[^@LY]+>4EM#D5]K3W%5*=@V=79P);;4J#85\U MA;+S+B4N-.(-*B(R,A:4)PJ052FU*G))IK2FGI33W4S\K4U)*4=,6<8.9] M "7Q[I7JLY^U>86[GHZ$%BFOM;:KK93C:_4?/8&1WF77<>*Z23;\D0M9UZI" M3,E=7F3(C+KTJ;I4NN;:VEDO=U)S?[B45X[PZI&=I*F%.E1WY-]98>RR;V*8 M(F !'[]YB^RYROZ9]/\ XWL!/.CC\31\S4Y$9K(? M6"\"17(#80G %AW[KI]FM??O-[1^:6LA0/29^(H_P!M#QID)V@^OKS:Y62. M!7I@P "'K[V^TV> \'GC;0;S>8;W:0Z: M$FXAMVEU8IUM"^GF2AQ3*#41'T4:$]?@(6UT5?/WJW.92Y9DFV:^B_LUJ']YO M5WS2V:+"Z,_Q%+^VGXT#.;/_ %]^;?*BO$%_$V L;_=G?LN<4^F?<'XWKQK MWTC_ (FEYFGR,@^?>L'X$20((&84 (EOO:'ZO' M$GZ9\V^8[(M3HL]87?F8^,239OY^KX"Y2"\+L)< !:>]F?[+GA3]#%9^-[@: MQ[7_ (FO///D17F:>L*OAFS81L\ %55W?<.5@O< MYYNTJFD,G.W]F>8^1MAN.DT[$?9V ETVVGGTJ6^G)B6I9J)3JE&M24*4:$[/ M;)UO+[-V4]ZA&/P.Y]@L3+)<_+Z3]XEUM'L&N$2(]QF?VY,VCZYY^\+R5N$ZP24QZ>:^OXRB;/IT7U3U(\-M#1=QD M5Y12QD[:IAQJ#:[.!Y;Z'E+*K!:W3ER,MI!JP5N !IW[^ M>;MX-VG>5\DGE-3>''^7 K_ #?UC5XUR(VU"*F- *8P;@%I 2!/=G?M1L4 M^AC<'XHKQ ^D?\,R\]3Y68;/O5[\.)8WC7L@P &#O<-X,ZV[A'&3-- M9^EBMMY"%9'J[.O9BD3M<[.JX;S609W<9!F4+^AIAJG'[%[DDGI6@]=E=U+*X5:&K4UOK=7:X2K(W MOH_9/&W;^P=%[>QY[&-BZSR2=C.35+IFZQ[5$42H]C5S/(ANSHKJ"XU,@3&^ MK4R$^T\V9H61C9NQO;?,;2G>VDN=;U(II^P]YIZ&MQIHL.C6IUZ4:U)XPDL4 M>2CUG8;$^V-W"-@=N7DSCVX,<]ON]=WIQ,7W9KQB03ZIS[V7Q7JDM[3K2/% MF%E"^MW2EHFM,7O/M/=+1_5&T\!W?K;"-NZMR6OS#7FQ<;K,KQ'(ZQ9JBV=/ M;1TR(ZU-N)1(A38YJ-F3%?0W)B26W&7D(=;6A.LUU:U[*XG:747"XIR<9)[C M7[:&M#6E:"O:E.=&HZ5183B\&BJ;[CWVAW//]\[E%^G#.1M#L]Z@L?[.C_+B M6+8_4J/FH>*C#$9@]1L![4OVE/!K]YO4GSMKA@=J/P[>_P!M4\5GBS+ZA6\V M^0M\>1IC$P,H9-<*?URN)/[S>AOTJ8H,;G/JBZ_MJOB2.BZ^JU/-RY&6 M[(U1*T T#]YG %Q\LTUM)AHU-6^/WF!63R4]$L. MX_8IR"F0XKIXKF-Y).\OP^$<_P"(:$_K'R!T\UR;:B"[FM;U;6;WG2GY6GCP MR5:KAX#/TH_0AM+&KDN>['U'A.A=4;RFM]5H>1JM<$70I8^&C26-*S?\ M XZUJ:V\KI=3;PH]C6SFE,2H/B1^*5H41*2I)DI"B M)23(R(QELCSW.-F^:8$]1>=ZN>7U4FLLU)(B)TB(_2=Z$EY)?@42DE^Q M?Z=_U$93TQ92LJS5T[7;^UIXUZ"T1N(K!.XMTWBXM_.4],J,GNP<9/HE'F\1 MX8-F3@ $W7L$\3G-*<6;'>V3U[Q):$QL7V=Z#! MFW'AY^VS[!:N>FTT5TS'>6IV3:.&5A='&T;N*3R&[EC5IINDWNP]U#]W7'WN M*T*)K;D%_P ^/H55]U%8QXMU=3['Z25K+MNM;&FPS9M M.06X\_S]B4Z1ID.8QBZZ_5E+$]/H@T1&K3![.4R:B-2RFJ62C0I!%K_TD7OI M.T7H\7W-O1C']Z6,WV))=0A&?UO*7WDUJA%+JO3[*)$8K\P@ M &@;WEF!+E]K/.I$9E3K-7MS3D^>LE((HT1S)EUB'E$I25*2J=8L MM]$D9]7"/IT(S*=]',DMIH)ZW2J)=;'D1FF# M (?'O;W_EYP@_IGO3\1ZQ%M=%7S][X%+EF2;9OYRKQ1Y60DQ< MQ+ +0GL5?9.\-_Z&9K^EO8(UIVW_%-YX-(+^)L !8W M^[._9 M "N>]YHU+)U_W-[W.U1G4P=ZZ=U9L!F8?F5'?FXW4R-0S8R%]30F1%C:V MC+<;\%)0\VHRZ+(SV"Z.+I5]FXT/=4*TX=1ORG_6^L3C(*BG8*&["377[KV2 M/:)\9HY"IM;"BM:R[J92X5K36$*UK)K1(4Y$L*^2W+A2FTN)6V:X\EE*R)23 M3U+Q(R'&<8SBX36,6L&N!GQI-8/4RX$X^;=IM_:)TWO''G([E-MW6&#;&@IB MFHVXS>88U6WJX"D+6X\Q(KGIRH[S+A^JRZVIMSHM*B&IE_:3L+ZM95/;TJLH M/]UM8]7#'A*SKTG1K3HRUQDUUF>OCR'4 16/>MMX1\6XHZ M T'$EDU<[>W-,SB?';?43CN):EQF5&EL26$++K'D9/L&J=0;A&DW(9^4C-)F MFS^B^R=7-*]\UW%*CS5X4W\6$NN2+9RCSKF=9ZHQPZK?:3(&8O$F %C1[LY MJ-_6_;&H,PEQ4,2-Z[DVCL]AQ2>DMVKJI=5J2"3_ )_YUMDW=8O/,(\$&V_Z MJ2_G34K7SI'NU<;22HIZ*%&$.J\9OQ]/%AN$'SZKY3,'%>XBE[/LD@L0(PH M 1+?>T/U>.)/TSYM\QV1:G19ZPN_,Q\8DFS?S]7P%RD%X782X "T)[%7V3O M#?\ H9FOZ6]@C6G;?\4WGAQ_EP*_S?UC5XUR(VU"*F- *8P;@%I 2!/ M=G?M1L4^AC<'XHKQ ^D?\,R\]3Y68;/O5[\.)8WC7L@P 1K_>$NU0 M7+;43O*[1^-E(Y(:/QU]>44E/"4Y:;BU+5D]-FT[<:,DW;+-<%2MZ;4^4E/S M(9R8)$\ZJ"AJQ=@=J/LJ[^R[V7_KJ\NY;U4YO0GP1EJEN)X2T+G8Y[)OM/=Z^^5[@OLF@ $GOW=[NN+XT;,A<+][9'Z6@=QY(A.LLBN9A M(@:AVQ=/DRW"<6,?^ M?1CW:6NI!7>D4_2J*^6BM*[Y=M^T.YY_OG< MHOTX9R)EL]Z@L?[.C_+B96Q^I4?-0\5&&(S!ZC8#VI?M*>#7[S>I/G;7# [4 M?AV]_MJGBL\69?4*WFWR%KD-72N@ K*/>$?M?>77^X/_ )8= M+#9#8+\)VG_E_G5"?9+ZLI?O>/(TQB8&4,FN%/ZY7$G]YO0WZ5,4&-SGU1=? MVU7Q)'1=?5:GFYYKK!>Q^)V8S8 M<4Y-OK6RJ=CUZ4)_G"BTZWZW(UFLC(TL1<6N)LE9>)*..GPZD1E0/ZEMF9;1 M]%-Y6HQYUWEM2G>0W^;3QA6>.]&A4J3>_P U;N#6R_Z2MKH[*]-%C;UY\RRS M:E4L9XZN=52J4%AORN*5*"W5SWIPQ3BJC\LS]D /@M*N MONJ^94VT-B?73V%QY<20CSLOLK^%*B\#)1&1&E1&2DJ(E),C(C&4R3.\VV^:8$]1>=ZN>7U4FLLU)(B)TB(_2=Z$EY)?@42DE^QOZ=_U$93TQ92LJS5 MT[7;^UIXUZ"T1N(K!.XMTWBXM_.4],J,GNP<9/HE'F\1X8-F3@ M 9Q]O#A]=\V.4&"ZD98FM8-#D)R[;=]$2M*:+7%%)CN7*4 MRDK0<6SR-]UFI@++SJ;F3FW30IMMSIC5U16_)ZNMK? BI>FS MI,M.BG8"[VDDX/-YQ\C9TW_J7-1/F:-V-)*5:HM&,*;CBI2B6,=/3U6/5%50 M45=#J*2CKH-/3U-=';B5]755D9J%7UT&*RE#,:'"B,(;:;01)0A)$1$1"HI2 ME.3G)XR;Q;WVS\0[JYN+VYJ7EW.56[K3E.:; M[TG@?)#2^SM#[.K4VN";6PV[PS(HQ):.3'BV\1;+%M6./-NIB7=%.]*= D$7 MGC38[3J.BD$8]5C>U\NO*=];/"O2FI+J;CX&M#6ZFT<:-6="K&M3]O%XHJ6N M3&@,WXL;^VUQXV,REO+]29K;XC926FELQ+B+#=)ZDR:M;=4IU-/E=#(BV<(U MGYSB2VS41&9D-I\MOZ.9V%+,+?YJK!27!OI\,7BGPHLBA6A<48UX>UDL?\.I MJ/#1[CM.4HJ.VR:[I\;H($BUO<@M:^CI:N(@ER[*VMI;,"M@1D&9$N1,F2$- MH+J752B'"$(IMO>2TMGQM13D]21;Q\5M'UO&GC7HG0-4<=R/J'5. M#X%(F124EFUM\?Q^#"OKSHLB5ZM]>-R)KG@GJX^KP(O M4_EKJU M92XDVVEU%@NH5I<5G7KSK/W4F^N]![X/ =( &H'O MT:_D;%[4'+2N@QU/V.-T.![ B*3ZQG&CX%M3!\HOI'IM/-)<2G%JV>D_4\Z$ M$KS^4U(3TEFPU=6^U-K)^UE*4?A0E%?YFC)Y//F9C3;U-M==-:^Y Q,_<@N.K6["Q[:.OL;I*GT4+?6EJ$_<:MLUD ME#:$D\IQ1FI2SZ4=TI6TH9K;W>'<5*'-QX83;?8FB'[1TVKFG5W)0PZJ;[:) M5@K CH !#X][>_\ +SA!_3/>GXCUB+:Z M*OG[WP*7+,DVS?SE7BCRLA)BYB6 6A/8J^R=X;_ -#,U_2WL$:T[;_BF\\. M/\N!7^;^L:O&N1&VH14QH $?[WF"I58]KC+YA042RH=R:?ME2% MLMNJJTO7='$^;M-!8XQ_?>VJBP)9)))3'DXQ?( M)HTK4:D>P7;!]5$D_,9ETZ$1GK[TDP<=I6WJE0@U_F7*F0C/TUF&._"/LDA@ M0$P@ 1+?>T/U>.)/TSYM\QV1:G19ZPN_,Q\8DF MS?S]7P%RD%X782X "T][,_V7/"GZ&*S\;W UCVO_ !->>>?(BO,T]85?#-FP MC9X (GWO67&N3F/'G0?*2DA*>E:5SRWUSFJX[1F MXG#=L1H$BFM[!WR&E,"BS+$F(37QDF3]_P# KS=4VET7YBJ-_7RR;T5H*59#"5587-P_*2Q MUI-=PNI'!X;C;)YDUJ[:R3DL*D^Z?5U+K=ELTB":&6.8Q['[G++^CQ;'*Z1; MY#DMQ68_0U,1*52[2YN9K%=5UT9*E(2J1-G24-((S(C4HO$<*E2%*G*K4>%. M*;;WDEBWU$?)248N4M$4L2W5XE:*K^,G&+0O'ZM-I;>H]4X5A$V4R:5(L[VG MHXC.271J0VRA3MYD)RIBS2A"36^9DDB\"U2S6^EF695[^7^K5E)<";T+J+!= M0K6YK.XN)UG[J3?:[!D,,>= 1+?>T/U>.)/TSYM\QV1:G19ZPN_,Q\8DF MS?S]7P%RD%X782X "T)[%7V3O#?^AF:_I;V"-:=M_P 4WGAQ_EP*_P W]8U> M- M_#B6-XU[(, 5\WO#/:J+BAMI7+;1^.^S\==XY&^G,*&HB(;K=/[ MOOD:46,9X #E+V]NL MHN[C)U+]I3P M:_>;U)\[:X8':C\.WO\ ;5/%9XLR^H5O-OD+7(:NE= !64>\ M(_:^\NO]P?\ RPZ6&R&P7X3M/_+_ #JA/LE]64OWO'D:8Q,#*&37"G]E.G.+U2A.+C*+X'%M'LR^_N\JS"AFEA-T[ZVK0JTYK7&I3DI MPDN&,DFN(A5[VH%2%(],I\6'*6FNM6D'XE'MZTVI M377H?IO)\"^ ?C!M;L[=;);37^S5[CZ19752ECAASHQD^9-<%2'-G'@DC]\] MB=J;/;;9'+MK+##T;,+.G6P3QYDI17/IM]]3GSJ7$D(\[+[*_A2HO R41D1I41DI*B)23(R M(QE,DSO-MG,VM\]R*XJ6N;VM15*56F\)0DMU;C36*E%IQE%N,DXMIM9K4W/I MR=K2R*=!-V=B5D^I-;-7\9Z \9*<^2[%1$1>LE!&;3G@3R$F?@HE$7['_IV_ M4)EG3)D[RW,_)VVWEG23N**T0KP6$?2;=/3S&VE4IZ71FTL7"4)/HE'F\1X< M-ES@ !]E=76%O80:FI@S+2UM)D:NK:VNC/S;"QL) MKZ(T.#!AQD.R9$5K9UUZ]&VHSN;F<:= MO3BY2E)J,8QBL92E)X)123;;:22Q98 =IS@3&X.\=X[&5PHJMZ[6^3LJVU8( M3'>>YH\RN_DW_P 6 MGHCP[\NKR8'XT_J,Z8:G2SMM*>73E]T&A^6M! 0S"W!BMCJS/WHZ"2D\TUL4:=BUK M/4:2-R;?X9=*AMF2E=&,?(C)/@:[LZ+\S=6RKY54?=49*OL\I$M%J$D-V_N_'%-7)ON0:LN+BJ588#QSCRN0&7..(, MHA6F'2(D;6D,WU+0TS+*KF%',G%2(D"3\0T)<4B%[>9I]F[/580>%>X^2 MCQ2]O_D4ECN-HQ.=7/H]C))]W/N5U=?8Q++P:YD# M #SC<6LZ+=6H]HZ=R?PQO:^N\TUO?J]%,@T4V;XW98U9.)84MM+JVX=FM2 M4^9/51%XE\(]%I)4+;TPG94)2V'B+R/,J2M M/5*B,;86ES2O;6G=T'C1JPC*/%)8KJZ=)9=*I&K3C5AIA))KJGG@]!S-N/9@ M[A\7MWF/T]#-L8TRCV!%KH[3\F?,P*Y:*0ZT MRVY)>JWIK+"%/.MD(IMAD#V@RET:.'IM)\^GCNO#3''A&-S6R] M.MG"'ST7C'CWNKRX%FQ@^S_7>58_G&#Y961[K&,MQ6V@WN/7U3+3 MYH]A56U:](A38KG0R\S:S(E$9'T,C(M;ZU"M;594+B,H5H/!QDFFGO-/2B S MA.G)PFFIK6GK.U#J.( 0^/>WO_+SA!_3/ M>GXCUB+:Z*OG[WP*7+,DVS?SE7BCRLA)BYB6 6A/8J^R=X;_P!#,U_2WL$: MT[;_ (IO/#C_ "X%?YOZQJ\:Y$;:A%3&@ :QN\QIZ7O+MA\Q,) MK8/RC:UNJW=EUD9MM3LMR58HV<+" F ML>Z<\CJ16*\GN)-G81XM_&R6FY"X96N.D4BZK;:II]=[%D1VCZ?%Q]_'L:)? M3J:BL"/H1(,Q3?2EE\_*VV:Q6--Q=*3WFFYPZ^,^L17:.@^=3N5[7#FOE7*R M8V*C(N $2WWM#]7CB3],^;?,=D6IT6>L+OS,?& M))LW\_5\!%V$N M/>S/]ESPI^ABL_&]P-8]K_Q->>>?(BO,T]85?#-F MPC9X ,?.5W'C$^6/&_:3,Q;*H\52VTOS\1RF'#LXR341'(B(ZF/?E>85/;756@J5]PZESK0^U-@:9V;3.X_G^LLLNL-RNI M=\RDQK>CFNPWW(CZD-E,K9A-D_%D)+TY,9QMU!FA:3/:BTNJ%]:T[RV?.H5( M*47P-Y/; MY[EM3+[C1SEC&6MPFO:R7%J:W8MK=/+>6L+RWE0GNZGO/;7@^HUN23W4UI3]G%%>W%O5MJKHUEA-?MBN!GO@\) MT@ : ^^KW9*#@SI*VTAJ'*8CW+C<- _74$:LE(>L-.X1;LOP[+ M:%PEKS_)UX\P2X^.,.FA;LU1S/*MF&MMV=[$[+3SN]5[=Q?V51EB\=522U06 M^MV;WM&MZ,SE&6RNZJK55_QHO3[Y[W;ZVZ5Q*E*6I2UJ4I:E&I2E&:E*4H^J ME*4?4S49GXF-A";U9O'**1B_E:FCJ;K]CJEC"-?2#@ $2WWM#]7CB3],^;?,= MD6IT6>L+OS,?&))LW\_5\!%V$N M">Q5]D[PW_H9FOZ6]@C6G;?\4WG MAQ_EP*_S?UC5XUR(VU"*F- *8P;@%I 2!/=G?M1L4^AC<'XHKQ ^D?\ M,R\]3Y68;/O5[\.)8WC7L@P !Y7O#2VN.1>I-@:/VYCL7*M<[,QN M;C&4TLHDD;L.62'(\Z!(-"UU]U36#+,VOEMD3T*=':?:-+C:5%ZK*\N,ONZ= M[:2<;BG)2B_8>^FM#6ZFTSLHU9T*L:U)X3B\5^W*59'<3X*['[>O)W,]!YTF M5:43*SR/5>>*BJCP=BZTM)$A./Y'&^(EIJSC&PY!M8R.J8EK%D-H4XT33KFS M>S^=V^?Y;"^H8*>J<=V$UK7%NQ>[%IZ\46'8WE.]MU6AKU-;SWNUP&"XS9ZP M V ]J7[2G@U^\WJ3YVUPP.U'X=O?[:IXK/%F7U"MYM\A:Y#5TKH M *RCWA'[7WEU_N#_P"6'2PV0V"_"=I_Y?YU0GV2^K*7[WCR-,8F!E#) MKA3^N5Q)_>;T-^E3%!CAFL_<.G[+65H4A@W9^*6+ZDU-HHB-QATR6X579>0B2B:V MV@S0LB)#Z$FI)$9+0C]E?T^?J R?IGR5VETJ=KMS9TD[JV3[F<4U'TFWQ;;H MRDTIQ;/\V>0&.JCSW&$V''S!;N&\U)@MOH6EO;=U7RVFR0])C+ZXZA:5>5M9V)$2 MCA.I@VTN=*6.6VKT?ZDEXJ_ZNMOGYT_JTZ?Z=RJW13L97QHI\W,;BG)-2:UV M<))ZD_K+6MKR#T>5BY3 A!^? :!/>6=80L\[6^=9=(:0J5I3:^H-C0'C2 MT;C3EUE*-0/H2M;B'$H=C;15YB02S,TIZIZ$:DSOHYN70VFA26JM2J0?4CY3 M_H,SD-1PS!1W)QDNQSO8*X<;"DY+$CW:KAJ_QVX//[URRK7 V'RWNH6>-HDL M&Q,@ZAQEN?5:JB.I6DU*1>E/M,@9=0OR/0+J+U2E39]=?^D7-UF&=>@TGC;V MB<>.H\'/K81AQQ9"<^NO+W?D8^TI+#]YZ^MH749(K%?F# M (5WO,7;&N47RNXMIC'USJ>?"I<=Y/4E6SYI%1/KVHM#B&WDQ6T M&;M7.@-Q::Z4@R]F>8A230I+\Q]JXNCC:2',^[]Y+":;=%O=3TRI\:>,H[^+ M6XDY5D.8+#T&J].N'LQ]E=7@(;HMXE &=/#[N3\S^"LQPN.>ZK_ !G%9D_Y M1N-:7K43+]8W,I?D*5)DX5D+,ZJK;*>TTAMZPKB@V2VT)3[01)3TP>;;.Y/G M:_\ 848RJI8*:[F:_>6#:6\\5P'DNK"UO%\O!.6_J?77LZ"0#J7WM#2ZR^!1$N6BDRFFVHA]WT_$VBFL(4OX%(+P*"77179 MR;=E=U(+>G!3[,7#D,+5V;I/YFK)<:3Y,#,K'_>RN+\F-YLJXL;ZII?H1%$Q MC^0:]R:-[2MM9SFO:K&UQ)TF([I))IST?,\DS-2&C(DGB*G19F2?R5U0:X5- M<6I2_;?/*]F[CW-2#ZC7;/1*SWKC@.[%)=SH[E] F^=9*CUF'Z8MXI-D9>FL MIDK>=(\I:B_E)] B3^!1CSRZ+L]3[BO:./#*HO\ \;Y3@]G+S'1.EAQR^*/YFN9WU>:/_ ,Q(X_E?G_TUG\.I_M'S[NWO?TNO+XH^]9]O'\S7,[ZO M-'_YB0_*_/\ Z:S^'4_VA]W;WOZ77E\4?>L^WC^9KF=]7FC_ /,2'Y7Y_P#3 M6?PZG^T/N[>]_2Z\OBC[UGV\?S-L^WC^9KF=]7FC_P#,2'Y7Y_\ 36?PZG^T/N[>]_2Z\OBC[UGV\?S- MU,$MPF9'LDM'G1YE>574NI].HKNM2E1JRHS]O"3B M^-/!F"E%PDX/6GAUCL0ZSB !#X][>_\O.$'],]Z?B/6(MKHJ^? MO? I*/*R$F+F)8 !:$]BK[)WAO_0S-?TM[!&M.V_XIO/#C_+@5 M_F_K&KQKD1MJ$5,: !\EA @VL";5V<2//K;*))@6$&6TA^)-@S M&5QY<24PX2FWH\EAQ2%H41I4E1D?@/L92C)2B\))XI\)]3:>*UE3KW&.'^1< M%^8>Y>/-Q#FM8_CV22;S6%O+2^I&3ZFR5]ZTP"\8EO$:)SR:9Q,*>IM;B&;: M'+CFLULK&TNS^;4\[RBCF$&O*2CA-=[-:)+@TZ5[UI[I8UC=1N[6%=>V:T\# M6O\ ;>,(1FCUGOO%_DMM;B#O37_(72UTBES[7EO\H02EH>D4UY6R67(-YB^2 M0&)$5RRQO)*F0[$F,I<;<-ITU-.-NI;<1X,RRZUS:RJ6%Y'G4*BP>^GK4D]Q MIZ5V<5H.FXH4[FC*A56,)+]FN%%AIP.[^'!_F'CM'49YG5!QDWBY'CQ[S7&V M\@@T6,S[924H6K -F6I5F+9+!F/F28T:2Y7W"EGY/8U$27'*"SS87.LHJ2G0 MA*YLMR=--M+WT%C)-;K6,>$A-YDUW:R;@G4H[Z6GJK6NRN$W<0IL*RB1K"NE MQ9\":RW)AS84AJ5$EQWDDMJ1&DL+<9?9=09&E:5&E1'U(Q#)1E%N,DU);C,4 MTT\'K/J'P^ $2WWM#]7CB3],^;?,=D6IT6>L+OS,? M&))LW\_5\!%V$N M/>S/]ESPI^ABL_&]P-8]K_Q->>>?(BO,T]85?#- MFPC9X B1>\C]JRSVK0N<_]"8VNPSK \?8KN1V M*4\-;UCEF!4C33%+M&OB1&E/S+K :])Q;GJ2U.4+3#_5M%:[ZUJ]'>T\;6?V M#?2PH3EC2D]49/7!\$GIC[[%>Z6$DR+,53?H59]PWW+WGO=7,@TBZR7 M;"^WKW+^2';@V1)S#3-O%NL)R9^$6RM/Y2Y*?P7/HD)+S4=^0U&<1*HLGK69 M"_8;6&:9#"C\CJ9$93D9R/Y_LYEVT-NJ5XG&M'VE2/MH]N+W8O1O8/2>*]L* M%]3YM5836J2UK_#@)ZG!SOH<$N:L"GI#V!"T%N2:AAF9J/<]I78Z_)LW"\IQ M\)SB2N+A^'%..])D.N\HO+1M\WGTM^.GKK6N3A-R25)6E*T*2M"TDI*DF2DJ2HNJ5)47 M4C29'U(R$0,6?H =+S_ &/KW5&+V.;[1SK#]<894(-RTRS.\EIL2QNN M0EMQXSFW=]-@5L;^:96HB6X1F23,O@,=U"WN+JJJ-M"=2L]48IR;ZBQ9SA3G M4ES*:?[CSW*]H[2RV[SO86<7$ MF^RO+ZWI>DEM.G"E!4Z:2@E@DCHX[SD>JZ/TILKD9MG!-(Z?QF M7EVQ]C7\7'<8HXG1'K2Y'F/5PHZ'#6Z3CB M]9-HP6I<>ZWNR;W"O;Z[G>W$JTM$=26\MQ=OA,Z1A#Q M@ $2WWM#]7CB3],^;?,=D6IT6>L+OS,?&))LW\_5\!%V$N M">Q5 M]D[PW_H9FOZ6]@C6G;?\4WGAQ_EP*_S?UC5XUR(VU"*F- *8P;@%I 2 M!/=G?M1L4^AC<'XHKQ ^D?\ #,O/4^5F&S[U>_#B6-XU[(, !J MI[N_;;Q?N/\ &*SPV''KZW?.MD6F6Z!S*6IN.F#D[L>/\JX7<35$2F\2V%$K MVHDSJHD1I;42:9+.(3:Y1LIM%5V>S)5FV[&IA&K'?CN22[Z&.*WUC'=,CEE_ M*QN.<_F9:)+@W^-=M;I6"YAB&4:^RS)<%S>AL\6S'#KVUQC*<;NHKD&WH<@H MYKU;;U%E#>)+D:;7SHZVG$'\"DF-DZ-6E7I1KT9*5&<4XM:4TUBFN!HG\91G M%3@\8M8I\!UP=IR V ]J7[2G@U^\WJ3YVUPP.U'X=O?[:IXK/%F7U"MYM\A M:Y#5TKH *RCWA'[7WEU_N#_Y8=+#9#8+\)VG_E_G5"?9+ZLI M?O>/(TQB8&4,FN%/ZY7$G]YO0WZ5,4&-SGU1=?VU7Q)'1=?5:GFYD78RTV_P!C;[9>ZYJG<4FZ4W_I MUX=U1J;^$9I<[#3*#E'5)E@]%FWM[T:;>9?MA9\Z4+:LE6@O]6WGW%>GO8RI MM\S'1&HH3UQ1#9R"AM\6O;K&;^"_67N/6MA27-;)3Y9$"TJI;L&?#>21F1.Q MI3"T*Z&9=2'X[7]C=Y7?5LMOX2I7UO5G3J0>N,X2<91?"I)IG[L99F-EG&76 M^;9;4C6RZZHPJTIQU3IU(J<)+@E%IKC.('D/< '$7M% M4Y-4S:2[A-6%98-&S)C/$?0RZD:'&UD9+9?961*;<29+0LB4DR,AGMF-I\]V M-SVVVEV:N:EKG-K4Y].I#B<)K&,X23C.+<9)IM'QI-8,UE[SU*VU)Q[E!RMQ:1"U3%=C7&K]37\-R/)V>^TI+\+ M+,QKI*$.LZY;427(<)Q)'?'T<<+Y.\J9\0S_ &@5NG96,L:^J4E[G@7OM]^Y MX]6C'ZEOU-4]G*=?8#HZN(SVBDG"[O*JMBP1B]K M;IR?:]] ;KM\2+7#'T3$"HI*:$Q6U59"83\5F) @QFVFTEX)0@B&KU2I.K4 ME5J-RJ2;;;UMMXMOC97,I.4G*6F3>+.8' ^ M''VU357]59T5[65]U1W5?-J;FFMH4:RJK:JLHSD.QK+.NF-O1)]?/B/+:>9= M0MMUM9I41I,R'*$Y4Y*<&XSB\4UH::U-/<:/J;B\5H:(5/=)]VKR6JM\CWEV M[8+5[C,Q3]MD'&"PL?1O\>>_\66_J#(+F6;&04SO53A4=@^U.BFDT0Y$PG&H MD>X]F>D6G*$;+:!\VJM"K):'YQ+4_?)8/=2P;M\HN<(V%B62X+F6.RUP+_$\PH[/&\DI9S9$I<2UI+B-#LH$@DJ( M_(ZVE70R/IT,6M1K4;BDJUO.,Z,EBI1:::X&M#)+"<*D5.#3@]36E'5QVG( M N#..'ZO&AOH8U=\QZ,:EYCZPK^>GXS*RK_ #\_#?*>SCQG M4 !#X][>_\O.$'],]Z?B/6(MKHJ^?O? I*/*R$F+ MF)8 !:$]BK[)WAO_ $,S7]+>P1K3MO\ BF\\./\ +@5_F_K&KQKD1MJ$5,: M &E/O2=J.F[D.DX=[@+551\IM00+"1J?(9S[5; S*FDNHF7&J MLNL5-+2FJMW6S?J9+QDBKM3\WG:C2IWJ3+8[:B>SMXX5\9996:YZ6EQ>Y.*W MUJDO=1WVHF5RK,78U<)XNWEKX.%>SOKJ%;7L376>:CS?)=:[/Q#(,"S[#K-Z MFRC$:]1EU#K2^AMO,N(<;4IM:5'L/;W%"[HQN; M:<:E":QC*+Q37 _VWB=PG"I!5*;3@]31TP=YR ]CUER*Y!:5Z?W-[UW)J7H MMYTO[LMG9M@?1R1T]=POR6NZKHM[H7G/X5?AZCQW.7V%Y],K*ACP1P["P1YGEF7O2Z4.M@>CI[Z7=@0 ME*2YDYL9)222-6&ZG6HR(NA>9:\ 4M:O#Q,S,S_"//\ >XEV?:XU164UU*$-)L+O MS,?&))LW\_5\!%V$N M/>S/]ESPI^ABL_&]P-8]K_Q->>>?(BO,T]85 M?#-FPC9X _*DI6E2%I2M"TFE25$2DJ2HNBDJ2 M?4C29'T,C $([O(^[U7V,666-./Q_-SYM98*%9ZI;RJ/!14(\$$UK_)E76%%Y2\"/V#KT\/@&'OL@R7,FY7 MMM1J3>N7-2E\)82[)Y:UE:7&FM3A)[^&GKK2;-L']Y=[I.)L(9OLTT_LYQ*/ M*QB7_,+_DMI3_/K\/!OTXW7Z.=F:KQIPK4O!J- M^/S_ -D>">0Y?+4I1XI/V<3WZL]ZXY\M2B7./Q3@ M++WJCN+3HCD:+J_A_3/+4@TSZW7&W79;1(62E);1;[XM8!I=27E5YF%'T/XI MD?0RYQZ,-GXO%U;MK>\,]U?9##\*-R J= M;5TCSD]#UGK'7U$_Y5>"4L7UKC]_E4/T_'H;$]M1]?$SZ%TREML#LO;O%T'4 ME[^8Y/A;?LX&J3;>^=W[\OCR?>&W]F;>R#JHV[?9.<9 M)FDV*A7@4>"[D-E8' B-(^(VRQZ;32")"$I21$4HM;&RL8>2LJ5.E3WH145U M<$L3(TJ-&C'FT8QC'@27(>3CUG8 ![AQWXV[NY7;2H=,\?\ 7M[LC8.0K\T> MHIF6T1:VO;<::EWV1W,QR-3XSCE.Z]U[R6MM[B2;.JO7I6U-U:TE&"_;1OO@+&;M%]GW6G;5P-_)[^75[ M%Y2Y[11*_9.R8S2W:+'('KG.=P+5R9\*'9P,5;D^E[;,>0U,NY$9M]YMAM$> M)'U]VKVMN=HZ_DJ:=/+*2T13P3;Q;@^9YG4OY\V/8H ");[VA^KQQ)^F?-OF.R+4Z+/6%WYF/C$DV;^?J^ N M4@O"["7 6A/8J^R=X;_ -#,U_2WL$:T[;_BF\\./\N!7^;^L:O&N1&VH14Q MH !3&#< M( "0+[LXE2NZ+BQI2HR1I;;ZEF1&9(2=56H)2C+^2DUK(NI_ MA,B$"Z1_PS+SU/E9AL^]7OPXEC<-?"# !$"]Y,[5S>74%AW# MM$8XA.58K7Q8W)W&JF*DEY%B5=';A56XFF6NBG+;$8C+4&[,DJ-ZI2Q*/TR@ MR5O6ST=[3^2J+(+Z7R4G\BWN2>NGQ2UQ]]BO=+"39%F/-EZ%6?]SKA;5XK5R+693;PQ7-[1##:U(@XS@3KN8Y/:25 MH0I+$>!1TKZ_,KHE2R2CKYE$(YM=6IT-F[R55X)T)17"Y=S%=5M'@S2<89?5 M-6BF]97X*0HO%N1'<+X[$EA?13;B3)25%U(279' M:[:#87:"WVHV7N)VN<6L^="<=37NH3CJG3FNYG"6,91>#/C6.AFLC:^J+C6- MQZ+WJ3L?G.+.ENB1T2\DNJO8IOE+R,63"/Y2?!+B2\Z/#J2?V@Z"^G39_IHV M?](M^9:[5VL(^EVG.TP>KRU''3.WF_:RTRIR?DZFGFRGT2CS>(\G%ZG$ M #E:*AO,HN:S'<:IK7(L@NYL>LIJ*BKIEO%26GR:C'"I.3 MNE*4)2E*22E)$E*4D1)2DBZ$E)%T(B(B\"$+-!FVWB]9_H'P CB^\_[H MAZ^[=5?JU$I)7._-TX+C2:Y+WIO.XU@AS=E75FIKJ7KQ*^^QJG867CY79K2O MP=2L+HULY5]H'/#+N$NJG)]1FA="X=(&T"S;,_0;:6-C;-K1JE4]U+A2]JN)M:)'S.[[TFX\C3?R-/1 MQRW7U-2ZN^2'1 #" &./(;B#Q@Y8T:* M#D;HS7&W(<>*[#KIV68[$?R2CCO&XIU.-9A$*)EF+K6IY9FNNFQ5]5&?7J8R M&7YMF65S\IE]>I2>.E1>A\0T58PFNL^QH[!K9SWW2O>%>Z]_= MAS!U3EC)&7H'GNN,NUZZI)]#,GBQZZVZR=QZN>;:AYUQ/OT+:]14FIV9L= MEEE?G4GT'$WNFJ60;O1)*ZH;6CH9?&Z]2+(PZ3=GI+%PNH\<(>Q49Z%M#8O6 MJBZB]B1T6R]V2[GT&6Y&BU&B;AE"4&F?6[<;:B.FM!*4EM%OCU5.)32C\JO, MRDNI>!F70S[X])&S4EBW73WG3[3:.:S_ "]K7-?N_P")R55[L)W-+&.M^8KC MQ0NI>4TF':[7LWI#B$H;64E"J/";F(3*U+-)$IU+GF0?5!)\IJXRZ2MFXO!> MD27!!>S)'Q[06"U<]]3_ !.3^ZZ]RK_X[QD^M'+/\,QQ_,O9SO;GX$?CGS[P M6&]4ZR[8^ZZ]RK_X[QD^M'+/\,P_,O9SO;GX$?CC[P6&]4ZR[9V2L]U9[BT^ M*4B5L[B#2/&M:#@V>R-MNRDI29$ETUTVB;>%Y'/^[T>-7\)$.N72?L_%X*E= MR6^H0]FJF<7M%8IZ(U7U%\8[;4^ZB=F:=H%,+)7@24H<(R\>I? .J72CDB]I0NFN%4U_P#D9Q>T=I[F%3_+\9GL MN'>Z6;C?GUJM@.MTJ6:B_(6E1RTX2M/< M-,IC54Y_'*39&V*.WNVH[BZVMN,DQG#IU!6S)22-IB7<1,7L7(Z%&1N(A.F7 M\@Q:_174@KN\I-KRDJ<&ENM)R3?4YRQXT279N2\K5CCW3BNPWVT0>A=)+0 + M2;LFXQD.(=K'AM2Y136%#;GKBWNODVTC.1)A5649]E^3X_.5'=)+B&+;'[B+ M+9,R(U,OH/IXC6;;.K3K;3WDZ34H>42Q6_&,8M=1IKJ%>YK*,LPJN+Q7.Y$D M;31&#'@ &N#G[VK^)?<5QQMG=.(O4>RJBO.!B.[<$.%3;*Q MUEOUW8M;*L'H,-29"UG66C,EAOU'%1CC/K]8I#D6T^:[/U,;.?.MF\9 M4Y8N#X<-<9<*P>_BM![K+,;FQE\D\:;UQ>I]I\*(97+KW:[GGH*;9W&D(M!R MNUTPZXY"G8&['QC94:"2U);5=ZSR.Q);TL_ O2I+*[49'YC)!=2*X,IZ14_*VE M2G5I;\)*2ZZ;1F*=6G57.I2C*.^FGR'GH]!S _P!2E2U)0A*E M+4HDI2DC4I2E'T2E*2ZF:C,_ A\!C8%A$:2R['D1\0QIA]A]M;3S#S M5-";=9>:<)*VW6UI-*DJ(C29=#&HUPTZ\VM7/?*RL)Z9OC9V\=)P -9G M=&[9N ]SO2F,ZORG8%[JK*,!RUS,L#SZFIVC4U[\OOYY?5=2,5*,E@UJ[.X1^/NB?_\ (/\ _I/_ /W*B>?FO_\ L/\ MY_\ ]$S7WE_['^?_ .T^N![HM ;FQ'+3G]+F5J)#2IT2!Q=9K9LF(E9&^S$L M)'(:U8A2'&^I(=7&D)0H^IMK(O*?&72M+FOFV"4MS&MBNMY)8]=![2O#11T^ M'_\ :2R>.^C,+XRZ-U7H#79V2\+U)A5)A-!)N9#4NYL(M/%2R[:V\EAB+&>M M;>6;DJ2;33+/K/*]-M"/*@JMS"]K9E>U;^XP\M5FY/#4L=Q<"U(C=>M.XK2K M3]O)XL]F'C.H #3+W".QOPVY\R;G/)53*T5 MO^T]62]N;65?!0O)+)3?D;D[,PA]46CSSQZ&Y*2Y773I(0@[$FD^F]>YQ/<[*X"'5RY]WR[B?% MYZTN,8URUR8US"4ZZQE^ARE9)D"(9+1[/\KZL?:8V$Q.4THU/)KH=M#CDA7F ME&7E4JV\JV]V?S-*%6IZ-]+1V=77P- M*>08]?XG9A8Y?3\K?5J=*'OY*./%B\6^!8LZJM>C0CSJTHQ7"\"29PL]UNY [ M"F565\U\^JM#X6:F9$K6FOK*GSG;]FW\53L&=?QDV>M\+2XVX1HDM/Y"Z2D* M0N(W\58KO..DRPMTZ634W7K=_-.--<.&BT-&"<;2+G/?>B/6UO ML<9,:XF\+.-/"+7B-:\;=7TF 4\A,-W(KELG;/,LVLH;2VV[C-=4TAUWV6&3JVXK+#)DV51YKG.8YU<>D9C5E4GN+5&*WHQ6A+LO=;9%[FZK MW<_*5Y.3W-Y<2W#*88P\X :YNY=VVM4]S+2M%JK8F5Y/KZ[PC*ORS MP#/<59A6,FCN7:R736$.WH+,VX>08_:P)?5Z.EZ'))^.PMN2VE+B'9#LYM%= M;.7DKJWC&I"<>;*,L5BL<5@UJ:>IX-8-Z-[W6%_4L*KJ02DFL&GV]PT(_=(= M>?MOYG]1='_B<)S^:M?^BA_%?Q#,?>2I]$OA/M']6/=(M;)>95)YMYP['2ZV M=9)9&ZVS(?4EEIMHD(36F99A7S2^JYA7JRQ>&A+<27 DDEBV M]&EMD?N*\[FM*O4PY\GB>[#PG2 1UMG^[#=N#8^9W^85M]R3U@TII2@DV!;=).T-O M1C1E&VJ\U)/YY>9W MUAZ/_P NP]'YH9_]#9_ J?[IS^\5[WE+K2^,;,. ':.X@]N"QRK)M$5>#Q4()J/.U8O%R;:3:6+T8O#6SP7N975\E<H)XX M)8+'?UM]DV=B-&/ #X+2KK+RLL:6ZKH%Q37$"75VU3:1(]A6 M6E981W(D^NL8$MMZ+-@38KRVGF74*;<;4:5$9&9#E&4H24X-J:>*:T--:FGN M-'U-IXK0T1\MN^[']M;:&:6V8T;_ " TK'N)HM@XA'PN)*F.>N^=37 M;$UML6SJ8GK*4;46/,;AQTJ]-EIMI*$(GMITD;16U%49^0K-+#G5(2YW5<)P M3XVL7NO$S5+/[^G!1?,GANR3Q[#1YA]U,[>/YY>9WUAZ/_R[#T_FAG_T-G\" MI_NG9]XKWO*76E\8V@]J M9F_DW#FU-'C6/4%(Y,CM.OLUM;#.8XRRJ2IXV&?3C6>[4YMM#S8WTHQMXO%0 M@G&&.K'!MMO>Q;PQ>&&+,?>9E=7V"K-*"W%H6._NM]5FRL1P\ M 1S^Y7[O-K[G_R0ON3F.&G!Z7CO/'3B:]?NB?_\ (/\ _I/_ /W* MC/\ YK__ +#_ .?_ /1/;]Y?^Q_G_P#M,CN)ONNNO./O(#5V[=C\M+W<=;JG M-,;V#3X)2Z6B:P8MLFQ"XB7^/IO;^1M78CS]$U;0&5R8K,1AR2VDV_702C&. MS7I+N+^PJV5O:QHRJP<')U.?@I+!X+F0TX/0\7AO'1<[03K494J=-0QM?XQM3!LHUWF=>BSQG+ MJB33VL570G":?(E,2XKAD9Q["NEMMR(SR?C,R&D+3T4DAA=HL@RS:G([K9[. M::JY;=T73G'=P>J47N3A)*<)+3&<5):49_9;:7-]CMHK/:C(:KHYM95XU:4VZRI1J;,Q^0G2#L-FO1WM3<[,YLL94I1XY3Y73S:&^A-SJ MVB]ZD['YSBSI;HD=$O)+ MJKV*;Y2\C%DPC^4GP2XDO.CPZDG]H.@OITV?Z:-G_2+?F6NU=K"/I=ISM,'J M\M1QTSMYOVLM,JIQ #9+PR[5O*[FA*K;G% ML2=UYJ:2MIV3N#8<.?3XQ)@J5_..X?!4RBUSN0:$K)'R>A4(G4^1^4QUZC#Y MCGECER<9RY]?O(Z7U=R/5T[R91?2C^H;HZZ+:=2US"Y5[M'%-*RMI1G54MQ5 MI8\RW6K'RCY^#QA3GJ)C7!SMA\:^"]9'L\+I5YSM^1!B>):D&Q"ZRGV3)$N5*\B5%7V9YU>9G+FU'S;?'1!:NKWSX]& M\D?F+TM=/NW72Y<2M\UJJTV9C-.G8T6U26'M959:)5ZBT/G5.XC+%TZ=/%HV M,#$%( !&FW)HIKNW=W2)79/"1=\(NV$AO%LR*4T[,QW;7)[(5UF59 M;K>$M2VX,B%CCT"EAY3&4VZII%"N(\GT[2.XW8UG?/9791RIOFYUF7=1WZ=% M8QC-[NG&3@_?8KVK,]2K?9N68QT7=QI6^H:D^KIPX^ DKI2E"4H0E*$(224I M21)2E*2Z)2E)="))$70B(5R8$_0 M .%R'&\=RVIE4&54-+DU%.]+VVER&K M@W53,]!Y$ACVJNLF),.1Z+[25H\Z#\JTDHO$B,MAXR#QG4 5#>4V9GT-2#Z?@'93JU:,_*492A-;J;3ZZ.492@^ M=!M2X-!@YGG:E[;>R7I$G*.$W'0I4KU#E3,8UM18',D..I>2X^_,P2/CER.(D*.^\A*#^2]T,WY&R;0MFOJ]N1*YI9$1&9DS\=7BKJ M9GUR,=O-JXK!7;PX:=)]ET\3O6T]^8W-/KNVU_:P/S"VI^GA_#A\4?;N9=^ MO@KM'8:GW=_M&5T=;$SC!9WSJGE.IF6V]^0K,AMM3;:"C(31[3I8ALH4@U$: MFE.>99]5FGRDGKGM_M7)XJY45P4J7LP9\>=YD]51+]V/LHY/[O=V@OV1?_\ M?G)[_&DA=.$]NMJYZ[M]2G27)!'%YSF3U MU7UHKD1W2H[(_:JI%/KA<,-:/'(2VEPK>SSO($I)LU>$7V762(JC\Y^8VB M0:_#S=>A=.F>V>U$_;7E31O**Y(HXO-LQ>NK+L=H]JP3MD=O+6EK3WV&<+>- ME9>X](AS:*\E:EQ"\N:>RKIT>RKK>NM,@K+2?#NZZ?$;=CSD.%+86GJAQ/B/ M'7VDS^YBX5KRX<):USY)--8--)I8-:UJ.J>87U1.,ZM3!\+7(9SC"'C M /'MN<>M"[^JRI=Y:6U7M M^K0RJ.Q#V5@.+YJB&A1K62J]60U=@[7/MN+-;;K"FW&G/CH4E1$8]=IF%]82 MY]E6JT9>\E*/7P:QZIVTJ]:B\:,Y1? VN0U@;*]WW[4FR'7IG_#8Y@-F_P"" MY^M=D;*Q=I*?54[Y6<>/*9^(,>*U%U17)5Y3)/7HE'EDMMMYM1;K#TGRD=Z< M(2[/-4NR9"GG68T]'E.3>ZJ=OZT\[N.;;Y78M(/T4I9_+35M MY5H0CKZRO9IVGVK-3SQ?A.;Y$G\"/P#,4^D_/HZ*E*UDO!FGV*F'8/5':*]7 MMHTWU&O^H\JM/=-.,+TDETO*C?-?#])!&Q:8]KZXDF\1J\[A2XE91M$TI)I( MD>B9D9&?F/KT+U1Z4\R2[NUH-\#FO99V+:2XW:<,>-G(5?NG/$QF,:+KDWR) ML)GJK,GZN!K6GC$R9)\C9Q)>+7CINI42C-?K$1D9%Y2Z=3XRZ4LU;[BVMTN% MS?\ U(^/:.YW*<,.KVSWS#O==^VIC+Z7KJYY,;#;)XW3BYCM+%X3"D&).$Y_/+^-X(\GAK=)>T=1805M3\&$GXTY'3+:"_EJ5./$G[ M+9G?J3LK]KK2[T67BG#G5][81D,E[=M+\H=S*>D,H,O;50MKWF8U+$IQQ1N' MZ$=E"%]#0E!)02<'=[8[37B:JW=6,7N0PI]F"B^NSQU+XSAE-#QW#\=HL4Q^O1Z<"BQNHKZ*F@M^'\W#K*N/%A1D>'P(0DA'*E6I M6FZE64I5'K;;;?5>D\,I2F^=)MRX3G1P.( M M !@[SIXD5W*+6*_D9F)#VOA;4JQP*W=\C*; E$ERPQ"TD&1? M^[;Q+1>BM1D468EMWJ39O);SU+87].W37==$&UR]/E.>QE_*,+RDL7S-R%S3C])2Q[I+YRDY0 MPYWDW&*+;U-G06ME1W<"757-//EU=K63V'(LZNL8#[D6;"F1G4I=8DQ9#2D+ M0HB-*DF1C\J[NTN;"ZJ6-[3G2O*-24)PDG&4)Q;C*,D]*E%IIIZFC]F+*]M, MRLZ68Y?5A6L:].-2G4@U*$X32E&<9+0XRBTTUH:9QX\YZ@ M #AK_'Z?**F727T!BQK9J/(]'?3UZ&7BAYEPNCC$AE7QD.(-*T*+J1D8 MD.RNU>T&Q.>T-I-E[JI:9S;2QA4@]SW4)Q?N-9V)OH]6QQ:=(4BJM_*1K;,R-Q,"S)"20Q.0CKY5="0^E)J1T,E(1^R? M0+^H+9[IFRA6U3F6FV]M23N;7'1))\UU[9MXSHMX M(\;&PQP [[KW5>SMMW18WJO7><;)R _3,Z7!,4O,LM$)=-9-N.PJ*#/D,M* M]-1^=2221)49GT(^G55KT:$>?7G&$-^3279,/G6T.0;-VGIVT-[:6-EW]Q6I MT8:-Q2J2BF]*T+3I6^;A^/'8)YJ[=7 L]I(Q/CKBRCPLXU+KW&8-I10)S1I63V/Z\8:+%(*&W4)<97.;M)L=Q/F;DI^ HG?;1YC M>8PC+R5%[D-#ZLM?6P7 :5=(GZJNE/;M5+*SN(Y-DD\5Y&SY4N6_+2 MQ6*DJ;I0DM#ILV[-MMM-H::0AMIM"6VVVTDAMMM!$E"$(21)2A*2Z$1>!$, M:UMN3EG[ ^ !B[RAV=G&,XU5ZMT>JO?Y';J^5,8U/\ *<4[ M&FP6+&:BHS+>.;0&C]1>!:AK;-F8^A7D1:7,BLIDN-R+1A19/++:A4J.YO4K?,0TOAWHKAEV%B]P[)QBXW:XX MG:6Q#2.L(TU5'C3$F7;Y%=OIGY;GN974A=GE^P\WMR;;7FSI!DE! M+<)IE#4=IEIOKS+,;C-;R=[=S5=6IK M>YN);B7 CWX> Z0 M M M M -1/<!D9'XD9&/SK::>#UGZEIIK%:C_ /H ! MQ]K55MY7RZFWA1["NG,J8E1)*"<9>;5^ R/Q2I)]#2I)DI"B)23(R(QETV/CU=A66QB-PR+#9%3@U->,3XR'4^I6RK"5+4EHG M6G7D>LEK]2NA;]5?YB6]/9[:#T:SVTA##0G&G=X:YTN=)J-7=G0UZY4\8\Z- M/4#]1.W?3WT:QEGVR=+*[C8=XIH;C MMM=?@00V"K9]F]?1*O)+WN$?%29H+GGZC^FS:",H7FT%Y2I/'1;*G:8)[BE; M0I3ZKDWPF>^,8EBN$T\;'L,QG'\1H(?7V2CQBFKJ"GB]4I2?LU951HD)CJE" M2^*@O B_@&+G4G4ESZDG*;W6\7UV4]F&99CFUU*]S2O6N;R6NI5G*I-\CPX\B0UVT:4JT^:FE%:6WJBMUO@XL6 MW@DFVD^4(N;P6A;KW$M]_MP+2=0UUKR316N1;!S!Z):[1SIJN8R&QAG)75X] MCM.Y-=QG7>*>V+4^WC6,?*VC\KBJN^OZ:?U0K((4.CWI)KR>2IQIV=[-X^CK5&A M<2;Q]'6A4ZKQ=!=Q/Y'"5&/PXVXTXMIU"VW6UJ;<;<2:'&W$&:5H6A1$I*TJ M+H9'XD8T"E&49.,DU)/!IZT]YGZ81E&<5.#3@UBFM*:>II[Q^1\.0 M !_:-)D0Y$>9#D/19<5YJ3%E1G5L2(TAA:76)$=]I2767F74D MI"TF2DJ(C(^HYTZE2C4C6HRE"K"2<9)M--/%--:4T]*:TIG75I4J]*5"O&,Z M,XN,HR2<91:P::>AIK0T]#6AF\WAKW2?315:TY.3UJ))-0:3;RD&M?E+HW'B MY]'8;-:S(NB?E5I)J/P.4@S]22-X.AW]4'-5+9OI,J-I81IW^O@4;I):=[R\ M=.IU5[:H?GCT[?H_YTJVUG1)32;QG5RW'!;\I6&M49)=* MK.7-A""YTZDN]A'LRDVH0BG.I*%.,I+(9?EMSF524:/-A1IQYU2I-\VG2@O= M3EN;T8I2J5)N-.E"=2482XRHQOK:EEN0-QI65K@OUT5;3CTB%C5/+>8DR**A M])&C=MG*^C;N-[.+J3GSW&.'-AH24%+!2F MHK'NIZ7*4Y1C",E"/&_J63J*EE\9*UA%+G2]O5:;QJ36+C!O'"-.+:A!1BY3 MGSZD^W#T'A M M M M #5MS<[=&/;Y. MSV;J9-=B>X%);Y24DO3I\G62?B3TI]*2OXLHNJBD-:O] M-?Z=\OV[\KM+LHJ=IM?IE4@^YHW;]_N4ZSW*J[F;T55I\I'<']/WZH\SZ.%1 MV2VT=6]V'34:R7_ &]VK;K=HM\Z"TT7@O)3C?Y;B&3X%D=OB&9T5EC6 M344M<&VI;>,Y$G0I"")1$MMPNBVGFU)<:=0:FGFE)6A2D*2H_P YLVRC,\AS M&ME&\UJ:>*E%X2C).,DI)I=<&.,J ! MF7Q@YQ;EXPRV*VDG%E^N5R/6L=<9'*?54D3CJG),C&[ DOR\5LGC<6HUL)7& M<<5YWX[YDGI+=&6F5";Q;QBG!MXSI MS:6%$=+OZ>MA.EVC*ZS"GZ#M2HX0OJ$5Y30L(JO#1&X@L$L)M5(Q7-IU::;Q MD-\=N<^@^1K4.NQ[)$8IG<@DH=U[F+L:JOW9'0B4BB?-Y59D[2U$HT%#=

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end EX-101.SCH 4 eypt-20241022.xsd XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 100000 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink Cover [Abstract] Amendment Flag City Area Code Document Period End Date Document Type Entity Address, Address Line One Entity Address, City or Town Entity Address, Postal Zip Code Entity Address, State or Province Entity Central Index Key Entity Emerging Growth Company Entity File Number Entity Incorporation, State or Country Code Entity Registrant Name Entity Tax Identification Number Local Phone Number Pre-commencement Issuer Tender Offer Pre-commencement Tender Offer Title of 12(b) Security Security Exchange Name Soliciting Material Trading Symbol Written Communications XML 6 R1.htm IDEA: XBRL DOCUMENT v3.24.3
Document And Entity Information
Oct. 22, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Oct. 22, 2024
Entity Registrant Name EyePoint Pharmaceuticals, Inc.
Entity Central Index Key 0001314102
Entity Emerging Growth Company false
Entity File Number 000-51122
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 26-2774444
Entity Address, Address Line One 480 Pleasant Street
Entity Address, City or Town Watertown
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02472
City Area Code (617)
Local Phone Number 926-5000
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.001
Trading Symbol EYPT
Security Exchange Name NASDAQ
EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.3 html 1 22 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document And Entity Information Sheet http://eyepointpharma.com/20241022/taxonomy/role/DocumentDocumentAndEntityInformation Document And Entity Information Cover 1 false false All Reports Book All Reports eypt-20241022.htm eypt-20241022.xsd http://xbrl.sec.gov/dei/2024 false false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "eypt-20241022.htm": { "nsprefix": "eypt", "nsuri": "http://eyepointpharma.com/20241022", "dts": { "inline": { "local": [ "eypt-20241022.htm" ] }, "schema": { "local": [ "eypt-20241022.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2024": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 23, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2024": 22 }, "report": { "R1": { "role": "http://eyepointpharma.com/20241022/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "C_468a2871-ca42-499b-923e-75399c884232", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "eypt-20241022.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_468a2871-ca42-499b-923e-75399c884232", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "eypt-20241022.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://eyepointpharma.com/20241022/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://eyepointpharma.com/20241022/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://eyepointpharma.com/20241022/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://eyepointpharma.com/20241022/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://eyepointpharma.com/20241022/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://eyepointpharma.com/20241022/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://eyepointpharma.com/20241022/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://eyepointpharma.com/20241022/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://eyepointpharma.com/20241022/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://eyepointpharma.com/20241022/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://eyepointpharma.com/20241022/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://eyepointpharma.com/20241022/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://eyepointpharma.com/20241022/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://eyepointpharma.com/20241022/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://eyepointpharma.com/20241022/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://eyepointpharma.com/20241022/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementTenderOffer", "presentation": [ "http://eyepointpharma.com/20241022/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://eyepointpharma.com/20241022/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://eyepointpharma.com/20241022/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SolicitingMaterial", "presentation": [ "http://eyepointpharma.com/20241022/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://eyepointpharma.com/20241022/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "WrittenCommunications", "presentation": [ "http://eyepointpharma.com/20241022/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "12" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 14 0000950170-24-116847-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-24-116847-xbrl.zip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end XML 15 eypt-20241022_htm.xml IDEA: XBRL DOCUMENT 0001314102 2024-10-22 2024-10-22 0001314102 false 8-K 2024-10-22 EyePoint Pharmaceuticals, Inc. DE 000-51122 26-2774444 480 Pleasant Street Watertown MA 02472 (617) 926-5000 false false false false Common Stock, par value $0.001 EYPT NASDAQ false